PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials funded by Région Centre Val de Loire

How to cite PKIDB:

Carles, F., Bourg, S., Meyer, C., and Bonnet, P. (2018). PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials. Molecules 23, 908. DOI:10.3390/molecules23040908
Bournez, C., Carles, F., Peyrat, G., Aci-Sèche, S., Bourg, S., Meyer, C. and Bonnet, P. (2020). Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB. Molecules 25, 3226. DOI:10.3390/molecules25143226

Acknowledgements:

To KLIFS from Vrije Universiteit Amsterdam to link our data on their database.

Latest update: 2021-07-28

Last approved inhibitors: Belumosudil

New inhibitors this month: Belumosudil, Ifidancitinib

Links to KinoMine data: Bioactivities, 3D structures and binding mode

Download sdf file: pkidb_2021-07-28.sdf

INN_Name BrandName Phase Applicants Links LigID pdbID Type RoF MW LogP TPSA HBA HBD NRB Indications Targets Kinase families Canonical_Smiles InChiKey First_Approval SC_Patent Chirality Synonyms FDA_approved Melting point
Toceranib
0 Pfizer ChemSpider
ChEMBL
PubChem
RCSB
PDBe
ZINC
FDA SRS
BindingDB
'BWC' 6m13 nan 0.0 396.2 3.1 77.2 3.0 3.0 5.0 nan KIT KIT Cc1c([nH]c(c1C(=O)NCCN2CCCC2)C)/C=C\3/c4cc(ccc4NC3=O)F SRSGVKWWVXWSJT-ATVHPVEESA-N nan None Achiral Molecule PHA-291639
TOCERANIB
Dezapelisib
0 Incyte Corporation ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 421.1 3.7 100.9 8.0 2.0 4.0 nan nan Cc1csc2n1c(=O)c(c(n2)[C@H](C)Nc3c4c([nH]cn4)ncn3)c5cccc(c5)F RSIWALKZYXPAGW-NSHDSACASA-N nan None Single Stereoisomer DEZAPELISIB
INCB040093
Oclacitinib
0 Pfizer ChemSpider
ChEMBL
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 337.2 1.5 91.0 5.0 2.0 5.0 nan JAK1
JAK2
JAK3
Tyr CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(c2ncnc3c2cc[nH]3)C HJWLJNBZVZDLAQ-HAQNSBGRSA-N nan None Single Stereoisomer JAKI
OCLACITINIB
PF-03394197
Fisogatinib
0 Blueprint Medicines ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
nan 1.0 502.1 4.5 94.6 7.0 2.0 7.0 nan nan C=CC(=O)N[C@H]1CCOC[C@H]1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1 MGZKYOAQVGSSGC-DLBZAZTESA-N nan None Single Stereoisomer BLU-554
BLU111362
FISOGATINIB
X439161
Recilisib
Ex-RAD;Ex-rad 1 Onconova Therapeutics ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
nan 0.0 336.0 3.6 71.4 3.0 1.0 5.0 nan nan c1cc(ccc1CS(=O)(=O)/C=C/c2ccc(cc2)C(=O)O)Cl KBEKQQJUNVQLDZ-MDZDMXLPSA-N nan None Achiral Molecule EX-RAD
ON 01210
ON 01210.NA
ON-01210
RECILISIB
Balamapimod
1 Wyeth ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
nan 2.0 573.2 6.5 82.2 9.0 1.0 7.0 nan RAF1
MAP2K1
MAP2K2
TKL
STE
Cn1ccnc1Sc2ccc(cc2Cl)Nc3c4cc(c(cc4ncc3C#N)N5CCC(CC5)N6CCCC6)OC CVAKNHIXTWLGJO-UHFFFAOYSA-N nan None Achiral Molecule BALAMAPIMOD
MKI-833
Empesertib
1 Bayer ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'8QW' 5n9s 6tnb nan 2.0 559.2 5.4 114.7 8.0 2.0 8.0 nan nan C[C@H](c1ccc(cc1)F)C(=O)Nc2ccc(cc2)c3ccc4nc(nn4c3)Nc5ccc(cc5OC)S(=O)(=O)C NRJKIOCCERLIDG-GOSISDBHSA-N nan None Single Stereoisomer
Pexmetinib
1 Array BioPharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 2.0 556.3 6.1 106.2 7.0 3.0 8.0 nan MAPK14
TEK
CMGC
Tyr
Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)NCc3cc(ccc3Oc4ccc5c(c4)cnn5CCO)F LNMRSSIMGCDUTP-UHFFFAOYSA-N nan None Single Stereoisomer
Puquitinib
1 Zhejiang Medicine ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
FDA SRS
nan 0.0 317.1 3.2 91.4 6.0 3.0 4.0 nan nan c1cc2cc(ccc2nc1)Nc3nc4c(c(n3)NC5CC5)[nH]cn4 QUTFBURLXCODBH-UHFFFAOYSA-N nan None Single Stereoisomer
Omipalisib
1 GlaxosmithKline ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'ZIG' 3l08 1 1.0 505.1 4.8 107.0 7.0 1.0 6.0 nan PIK3CA
MTOR
Atypical COc1c(cc(cn1)c2ccc3c(c2)c(ccn3)c4ccnnc4)NS(=O)(=O)c5ccc(cc5F)F CGBJSGAELGCMKE-UHFFFAOYSA-N nan None Achiral Molecule GSK-2126458
GSK2126458
OMIPALISIB
Epitinib
1 Hutchison MediPharma ChemSpider
PubChem
ZINC
FDA SRS
nan 0.0 430.2 3.5 82.6 6.0 2.0 5.0 nan nan CCN1CCN(CC1)C(=O)NC2=C(C=C3C(=C2)C(=NC=N3)NC4=CC=CC(=C4)C#C)OC CCN1CCN(CC1)C(=O)NC1=CC2=C(NC3C=C(C=CC=3)C#C)N=CN=C2C=C1OC DQAZPZIYEOGZAF-UHFFFAOYSA-N nan None Single Stereoisomer
HMPL-813
Alofanib
1 Russian Pharmaceutical Technologies ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
nan 0.0 413.1 3.5 139.5 6.0 2.0 6.0 nan nan Cc1cc([N+](=O)[O-])c(NS(=O)(=O)c2cccc(C(=O)O)c2)cc1-c1cccnc1 QUQGQIASFYWKAB-UHFFFAOYSA-N nan None Achiral Molecule ALOFANIB
Agerafenib
1 Ignyta ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 2.0 517.2 5.9 120.6 8.0 2.0 7.0 nan nan CC(C)(c1cc(no1)NC(=O)Nc2cccc(c2)Oc3c4cc(c(cc4ncn3)OC)OC)C(F)(F)F DKNUPRMJNUQNHR-UHFFFAOYSA-N nan None Achiral Molecule AB-024
AC-013773
AGERAFENIB
CEP-32496
RXDX 105
RXDX-105
Theliatinib
1 Hutchison MediPharma ChemSpider
PubChem
ZINC
FDA SRS
nan 0.0 442.2 3.5 82.6 6.0 2.0 4.0 nan nan CN1CC[C@H]2[C@@H]1CN(C2)C(=O)Nc3cc4c(cc3OC)ncnc4Nc5cccc(c5)C#C FSXCKIBROURMFT-VGSWGCGISA-N nan NaN NaN XILIERTINIB
Selatinib
1 Qilu Pharmaceutical ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
FDA SRS
BindingDB
nan 2.0 564.1 6.5 89.3 7.0 2.0 11.0 nan EGFR
ERBB2
Tyr CS(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F OAMVGUFHZPRXOM-UHFFFAOYSA-N nan NaN NaN
Altiratinib
1 Deciphera Pharmaceuticals ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 510.2 5.0 109.4 5.0 3.0 8.0 nan MET
TEK
KDR
NTRK1
Tyr c1cc(ccc1NC(=O)C2(CC2)C(=O)Nc3cc(c(cc3F)Oc4ccnc(c4)NC(=O)C5CC5)F)F GNNDEPIMDAZHRQ-UHFFFAOYSA-N nan None Achiral Molecule ALTIRATINIB
DCC-2701
DP-5164
Cenisertib
1 EMD Serono ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 451.2 2.5 99.4 7.0 3.0 6.0 nan AURKA
AURKB
AURKC
Other Cc1cc(ccc1N2CCN(CC2)C)Nc3ncc(c(n3)N[C@@H]4[C@@H]5C[C@H]([C@@H]4C(=O)N)C=C5)F KSOVGRCOLZZTPF-QMKUDKLTSA-N nan None Racemic Mixture AS-703569
R-763
Tafetinib
1 Nanjing Yoko Biomedical ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 424.2 3.7 77.2 3.0 3.0 6.0 nan KDR
FLT4
FLT1
Tyr CCN(CC)CCNC(=O)c1c([nH]c\2c1CCC/C2=C/3\c4cc(ccc4NC3=O)F)C KGSRYTUWXUESJK-FXBPSFAMSA-N nan None Achiral Molecule SIM 010603
SIM-010603
TAFETINIB
Glumetinib
1 HaiHe Phaemaceutical ChemSpider
ChEMBL
PubChem
DrugBank
FDA SRS
nan 1.0 459.1 2.1 117.8 11.0 0.0 4.0 nan nan Cn1cc(-c2cnc3cnn(S(=O)(=O)c4cnc5ccc(-c6cnn(C)c6)cn45)c3c2)cn1 RYBLECYFLJXEJX-UHFFFAOYSA-N nan None Achiral Molecule GLUMETINIB
Zotiraciclib
1 S*BIO ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 372.2 4.7 50.3 5.0 1.0 0.0 nan nan CN1C/C=C/CCOc2cccc(c2)-c3ccnc(n3)Nc4cccc(c4)C1 VXBAJLGYBMTJCY-NSCUHMNNSA-N nan None Achiral Molecule EX45
SB-1317
SB1317
TG-02
TG02
ZOTIRACICLIB
Repotrectinib
1 TP Therapeutics ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 355.1 2.6 80.6 6.0 2.0 0.0 nan nan CC1CNC(=O)C2=C3N=C(C=CN3N=C2)NC(C4=C(O1)C=CC(=C4)F)C FIKPXCOQUIZNHB-WDEREUQCSA-N nan None Single Stereoisomer REPOTRECTINIB
TPX-0005
TRX-0005
Elimusertib
1 Bayer ChemSpider
PubChem
nan 0.0 375.2 2.6 84.8 7.0 1.0 3.0 nan nan CC1COCCN1c2cc(c3ccnc(c3n2)c4ccn[nH]4)c5ccnn5C YBXRSCXGRPSTMW-UHFFFAOYSA-N nan NaN NaN
BAY 1895344
BAY1895344
BAY-1895344
Nedisertib
1 Merck ChemSpider
PubChem
BindingDB
nan 0.0 481.1 3.8 93.5 8.0 1.0 5.0 nan nan COc1ccc(nn1)C(c2cc(c(cc2Cl)F)c3c4ccc(cc4ncn3)N5CCOCC5)O MOWXJLUYGFNTAL-UHFFFAOYSA-N nan None Single Stereoisomer M-3814
M3814
MSC 2490484A
MSC2490484A
MSC-2490484A
Vecabrutinib
1 Sunesis Pharmaceuticals ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
FDA SRS
nan 1.0 529.2 2.7 130.5 7.0 3.0 5.0 nan nan c1c(cc(cc1N[C@@H]2CCCN(C2=O)[C@H]3CN(CC[C@@H]3C(=O)N)c4c(c(ncn4)N)F)Cl)C(F)(F)F QLRRJMOBVVGXEJ-XHSDSOJGSA-N nan None Single Stereoisomer BIIB-062
BSK-4841
FP-0182
FP0182
SNS-062
VECABRUTINIB
Lifirafenib
1 BeiGene ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
'3K3' 4r5y nan 1.0 478.1 5.3 89.1 5.0 2.0 3.0 nan nan c1cc2c(cc1C(F)(F)F)[nH]c(n2)[C@H]3[C@H]4[C@@H]3Oc5c4cc(cc5)Oc6ccnc7c6CCC(=O)N7 NGFFVZQXSRKHBM-FKBYEOEOSA-N nan None Single Stereoisomer BGB 283
BGB-283
LIFIRAFENIB
Mubritinib
1 Takeda ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 1.0 468.2 6.1 66.0 6.0 0.0 10.0 nan EGFR
ERBB2
Tyr c1cc(ccc1CCCCn2ccnn2)OCc3coc(n3)/C=C/c4ccc(cc4)C(F)(F)F ZTFBIUXIQYRUNT-MDWZMJQESA-N nan None Achiral Molecule MUBRITINIB
TAK-165
Olafertinib
1 Suzhou NeuPharma ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 530.2 4.6 93.6 7.0 3.0 8.0 nan nan C=CC(=O)Nc1cccc(-c2cccc3cnc(Nc4ccc(N5CCN(CCO)CC5)c(F)c4F)nc23)c1 IDRGFNPZDVBSSE-UHFFFAOYSA-N nan None Achiral Molecule CK-101
OLAFERTINIB
RX-518
Fadraciclib
1 Cyclacel pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 397.3 3.6 100.8 8.0 3.0 8.0 nan nan CC[C@@H]([C@@H](C)O)Nc1nc(c2c(n1)n(cn2)C(C)C)NCc3cnc(cc3C)C DLPIYBKBHMZCJI-WBVHZDCISA-N nan None Unknown CYC-065
CYC065
Henatinib
1 Jiangsu Hengrui Medicine ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 468.2 2.0 97.9 5.0 3.0 5.0 nan KDR Tyr Cc1c([nH]c2c1C(=O)N(CCC2)C[C@@H](CN3CCOCC3)O)/C=C\4/c5cc(ccc5NC4=O)F MCTXSDCWFQAGFS-UEXNTNOUSA-N nan None Single Stereoisomer
Peposertib
1 Merck ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB
nan 0.0 334.2 1.3 114.7 8.0 2.0 8.0 nan nan COCCOc1c(cc(cc1OC)Cc2cnc(nc2N)N)OC WSWJIZXMAUYHOE-UHFFFAOYSA-N nan NaN NaN TETROXOPRIM 154.0 °C
Ravoxertinib
1 Genentech ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'6QB' 5k4i 5k4j 6oph nan 0.0 440.1 3.2 97.9 8.0 2.0 6.0 nan nan Cn1c(ccn1)Nc2nccc(n2)c3ccn(c(=O)c3)[C@H](CO)c4ccc(c(c4)F)Cl RZUOCXOYPYGSKL-GOSISDBHSA-N nan None Single Stereoisomer GDC-0994
GDC0994
RAVOXERTINIB
RG-7842
Panulisib
1 Piramal Enterprises ChemSpider
PubChem
Guide to Pharmacology
ZINC
nan 1.0 527.2 4.8 134.5 9.0 1.0 3.0 nan PIK3CA
MTOR
Atypical CC(C)(C#N)c1ccc(cn1)n2c3c4cc(ccc4ncc3n(c2=NC#N)C)c5cc(c(nc5)N)C(F)(F)F VJLRLTSXTLICIR-UHFFFAOYSA-N nan None Single Stereoisomer
Orelabrutinib
1.5 InnoCare Pharma ChemSpider
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 427.2 4.5 85.5 4.0 1.0 6.0 nan nan C=CC(=O)N1CCC(CC1)C1=CC=C(C(N)=O)C(=N1)C1C=CC(=CC=1)OC1C=CC=CC=1 MZPVEMOYADUARK-UHFFFAOYSA-N nan NaN NaN
Dubermatinib
1.5 Tolero Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 515.2 3.6 93.7 8.0 2.0 8.0 nan nan CN1CCN(CC1)Cc2ccc(cc2)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)N(C)C)Cl YUAALFPUEOYPNX-UHFFFAOYSA-N nan None Achiral Molecule DUBERMATINIB
HCL-2084
TP 0903
TP-0903
TP0903
Ningetinib
1.5 HEC Pharm ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB
nan 2.0 556.2 5.4 107.6 8.0 2.0 8.0 Ningetinib, also known as CT-053 or DE-120, is a VEGF and PDGF inhibitor potentially for the treatment of wet age-related macular degeneration. nan Cc1c(c(=O)n(n1C)c2ccccc2)C(=O)Nc3ccc(c(c3)F)Oc4ccnc5c4ccc(c5)OCC(C)(C)O VQYYQSZNRVQLIS-UHFFFAOYSA-N nan NaN NaN CT-053 FREE BASE
CT-053-PTSA FREE BASE
CT053PTSA FREE BASE
NINGETINIB
Samuraciclib
1.5 Imperial College of Science, Technology and Medicine ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'I74' 5jq5 7b5o 7b5q nan 0.0 394.2 2.8 86.5 7.0 4.0 7.0 nan nan CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12 YCVGLKWJKIKVBI-MJGOQNOKSA-N nan None Single Stereoisomer CT-7001
CT7001
ICEC-0942
ICEC0942
SAMURACICLIB
Selitrectinib
1.5 Bayer ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 380.2 2.7 75.4 6.0 1.0 0.0 nan nan C[C@@H]1CCc2c(cc(cn2)F)[C@H]3CCCN3c4ccn5c(n4)c(cn5)C(=O)N1 OEBIHOVSAMBXIB-SJKOYZFVSA-N nan None Single Stereoisomer LOXO-195
SELITRECTINIB
Lerociclib
1.5 G1 Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 474.3 3.5 91.2 8.0 2.0 4.0 nan nan CC(C)N1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O YPJRHEKCFKOVRT-UHFFFAOYSA-N nan None Achiral Molecule G1T38
G1T38 FREE BASE
LEROCICLIB
Bimiralisib
2 Piqur Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'A3W' 5oq4 nan 0.0 411.2 1.0 103.2 8.0 2.0 3.0

Bimiralisib (PQR309) is a novel dual inhibitor of phosphoinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) kinases, with expected utility as an anti-cancer agent.

nan c1c(c(c[nH]c1=N)c2nc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F ADGGYDAFIHSYFI-UHFFFAOYSA-N nan None Achiral Molecule BIMIRALISIB
NC-B5
NCB5
PI3K-IN-2
PQR-309
PQR309
Apitolisib
2 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'980' 3tl5 nan 1.0 498.2 0.9 133.8 11.0 2.0 5.0 nan PIK3CA
MTOR
Atypical Cc1c(sc2c1nc(nc2N3CCOCC3)c4cnc(nc4)N)CN5CCN(CC5)C(=O)[C@H](C)O YOVVNQKCSKSHKT-HNNXBMFYSA-N nan None Single Stereoisomer APITOLISIB
G-038390
G-038390.1
GDC-0980
GDC-0980.1
RG-7422
RG7422
Foretinib
2 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'88Z' 3lq8 5ia4 6i2y 6sd9 6sdc 2 2.0 632.2 5.8 111.2 8.0 2.0 12.0 nan MET
KDR
Tyr COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F CXQHYVUVSFXTMY-UHFFFAOYSA-N nan None Achiral Molecule EXEL-2880
FORETINIB
GSK-089
GSK-1363089
GSK-1363089G
GSK089
GSK1363089G
XL-880
XL880
Poseltinib
2 Hanmi Pharmaceutical ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 470.2 4.6 95.8 8.0 2.0 7.0 nan nan CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccoc4c(n3)Oc5cccc(c5)NC(=O)C=C LZMJNVRJMFMYQS-UHFFFAOYSA-N nan None Achiral Molecule HM71224
LY3337641
POSELTINIB
Ceralasertib
2 Astrazeneca ChemSpider
PubChem
nan 0.0 412.2 2.9 107.8 7.0 2.0 4.0

Ceralasertib, also known as AZD6738, is an orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis.

nan CC1COCCN1c2cc(nc(n2)c3cncc4c3cc[nH]4)C5(CC5)S(=N)(=O)C DTTJKLNXNZAVSM-UHFFFAOYSA-N nan None Single Stereoisomer AZD6738
Branebrutinib
2 Bristol Myers Squibb ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 370.2 2.1 91.2 3.0 3.0 3.0 nan nan CC#CC(=O)N[C@H]1CCCN(C1)c2c(cc(c3c2c(c([nH]3)C)C)C(=O)N)F VJPPLCNBDLZIFG-ZDUSSCGKSA-N nan None Single Stereoisomer BMS-986195
BRANEBRUTINIB
Mavelertinib
2 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 415.2 0.7 115.0 10.0 2.0 6.0 nan nan Cn1cc(c(n1)OC)Nc2c3c(nc(n2)N4C[C@H]([C@@H](C4)F)NC(=O)C=C)n(cn3)C JYIUNVOCEFIUIU-GHMZBOCLSA-N nan None Single Stereoisomer MAVELERTINIB
PF-06747775
Silmitasertib
2 Senhwa Biosciences ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'3NG' 3nga 3pe1 5o11 6fyl 6fyp 6fyv 6hmb 6isj 6k3l 6khd 6khe 6khf 6p5s 1 0.0 349.1 4.9 75.1 4.0 2.0 3.0 nan CSNK2A1
CSNK2A2
Other c1cc(cc(c1)Cl)Nc2c3ccncc3c4ccc(cc4n2)C(=O)O MUOKSQABCJCOPU-UHFFFAOYSA-N nan None Achiral Molecule CX 4945
CX-4945
CX4945
SILMITASERTIB
Defactinib
2 Verastem ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'7KD' 5mah 1 1.0 510.1 2.4 142.1 9.0 3.0 8.0 nan PTK2
PTK2B
Tyr CNC(=O)c1ccc(cc1)Nc2ncc(c(n2)NCc3c(nccn3)N(C)S(=O)(=O)C)C(F)(F)F FWLMVFUGMHIOAA-UHFFFAOYSA-N nan None Achiral Molecule DEFACTINIB
PF-04554878
VS-6063
Derazantinib
2 ArQule ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
nan 1.0 468.2 5.5 59.1 5.0 2.0 9.0 Derazantinib (ARQ087) is an orally bioavailable, non-selective FGFR inhibitor being investigated for antineoplastic activity. nan COCCNCCc1cccc(c1)Nc2ncc3c(n2)-c4ccccc4[C@@H](C3)c5ccccc5F KPJDVVCDVBFRMU-AREMUKBSSA-N nan None Single Stereoisomer ARQ 087
ARQ-087
ARQ087
DERAZANTINIB
Riviciclib
2 Piramal Enterprises ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 401.1 3.3 94.1 6.0 3.0 3.0 nan CDK1
CDK4
CDK9
CMGC CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O QLUYMIVVAYRECT-OCCSQVGLSA-N nan None Racemic Mixture
Elsubrutinib
2 Abbvie ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
nan 0.0 297.1 2.2 79.2 2.0 2.0 3.0 nan nan C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1 UNHZLHSLZZWMNP-LLVKDONJSA-N nan None Single Stereoisomer ELSUBRUTINIB
Entospletinib
2 Gilead Sciences ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'CG9' 4puz 1 0.0 411.2 3.9 83.4 7.0 2.0 4.0 nan SYK Tyr c1cc(ccc1Nc2c3nccn3cc(n2)c4ccc5cn[nH]c5c4)N6CCOCC6 XSMSNFMDVXXHGJ-UHFFFAOYSA-N nan None Achiral Molecule ENTOSPLETINIB
GS-9973
SYK INHIBITOR GS-9973
Brepocitinib
2 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'G4J' 6dbm 6dbn nan 0.0 389.2 1.8 79.2 7.0 1.0 4.0 nan nan Cn1cc(cn1)Nc2nccc(n2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F BUWBRTXGQRBBHG-MJBXVCDLSA-N nan None Single Stereoisomer BREPOCITINIB
PF-06700841
Dilmapimod
2 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 0.0 456.1 2.9 100.3 7.0 3.0 6.0

Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others.

MAPK14
MAPK11
MAPK13
MAPK12
CMGC Cc1cc(ccc1c2c3ccc(=O)n(c3nc(n2)NC(CO)CO)c4c(cccc4F)F)F ORVNHOYNEHYKJG-UHFFFAOYSA-N nan None Achiral Molecule DILMAPIMOD
GW-681323
SB-681323
SB681323
Mivavotinib
2 Takeda ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
FDA SRS
BindingDB
'7KG' 5tr6 nan 0.0 344.2 1.5 97.9 6.0 3.0 3.0 nan nan Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1 MJHOMTRKVMKCNE-NWDGAFQWSA-N nan None Single Stereoisomer MIVAVOTINIB
TAK-659F
Lucitanib
2 Clovis Oncology ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'3ZC' 4rwl 1 0.0 443.2 4.4 95.7 6.0 2.0 7.0 nan FLT1
KDR
FLT4
FGFR1
FGFR2
Tyr CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC CUDVHEFYRIWYQD-UHFFFAOYSA-N nan None Achiral Molecule AL-3810
CO-3810
E-3810
LUCITANIB
S 80881
S-80881
Miransertib
2 Merck ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
'6S1' 5kcv nan 1.0 432.2 5.1 95.6 6.0 2.0 4.0 nan nan c1ccc(cc1)c2ccc3c(n2)n(c(n3)c4cccnc4N)c5ccc(cc5)C6(CCC6)N HNFMVVHMKGFCMB-UHFFFAOYSA-N nan None Achiral Molecule ARQ 092
ARQ 092 FREE BASE
ARQ-092
MIRANSERTIB
Leniolisib
2 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'9NQ' 5o83 nan 0.0 450.2 2.9 83.5 7.0 1.0 5.0 nan nan CCC(=O)N1CC[C@@H](C1)Nc2c3c(ncn2)CCN(C3)c4cc(c(nc4)OC)C(F)(F)F MWKYMZXCGYXLPL-ZDUSSCGKSA-N nan None Single Stereoisomer CDZ173-NX
LENIOLISIB
Berzosertib
2 Vertex Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 463.2 3.9 124.0 8.0 2.0 7.0 nan nan CC(C)S(=O)(=O)c1ccc(cc1)c2cnc(c(n2)c3cc(no3)c4ccc(cc4)CNC)N JZCWLJDSIRUGIN-UHFFFAOYSA-N nan None Achiral Molecule BERZOSERTIB
M-6620
M6620
VE-822
VX-970
VX970
Tarloxotinib
2 Threshold Pharmaceuticals ChemSpider
ChEMBL
PubChem
FDA SRS
nan 1.0 679.0 1.6 140.8 9.0 2.0 9.0 nan EGFR Tyr Cn1cnc(c1C[N+](C)(C)C/C=C/C(=O)Nc2cc3c(cn2)ncnc3Nc4ccc(c(c4)Br)Cl)[N+](=O)[O-].[Br-] WAKIMVYUBWMMHJ-FXRZFVDSSA-N nan None Achiral Molecule TARLOXOTINIB BROMIDE
Pegcantratinib
2 Cephalon ChemSpider
ChEMBL
PubChem
nan 1.0 536.2 4.1 104.0 8.0 1.0 3.0 nan nan COCCN1C(=O)O[C@@]2(C[C@H]3O[C@]2(C)n2c4ccccc4c4c5c(c6c7ccccc7n3c6c42)C(=O)NC5)C1=O SHWPFRVVBIKGAT-LYWBODIJSA-N nan None Single Stereoisomer CT-327
CT327
PEGCANTRATINIB
SNA-120
Tomivosertib
2 Effector Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'N45' 6ck6 nan 0.0 340.2 1.6 114.9 7.0 3.0 2.0

Tomivosertib, also known as eFT508 is a MNK1/2 inhibitor. Tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling

nan Cc1cc(c(=O)n2c1C(=O)NC23CCCCC3)Nc4cc(ncn4)N HKTBYUWLRDZAJK-UHFFFAOYSA-N nan None Achiral Molecule EFT 508
EFT-508
EFT508
TOMIVOSERTIB
Eganelisib
2 Intellikine ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'V7Y' 6xrl 7jwz nan 1.0 528.2 3.2 125.1 9.0 2.0 4.0 nan nan C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)C#Cc4cnn(c4)C)NC(=O)c5c(nn6c5nccc6)N XUMALORDVCFWKV-IBGZPJMESA-N nan NaN NaN EGANELISIB
IPI-549
Bemcentinib
2 BerGenBio ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 506.3 4.9 97.8 8.0 2.0 4.0 nan AXL Tyr c1ccc-2c(c1)CCCc3c2nnc(c3)n4c(nc(n4)Nc5ccc6c(c5)CC[C@H](CC6)N7CCCC7)N KXMZDGSRSGHMMK-VWLOTQADSA-N nan None Single Stereoisomer BEMCENTINIB
BGB 324
BGB-324
BGB324
CS-1046
HY-15150
KB-80319
QC-11751
R 428
R-428
R428
SYN-1131
SYN1131
W-5845
Voxtalisib
2 Sanofi ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB
nan 0.0 270.1 1.1 102.5 6.0 2.0 2.0 nan PIK3CA
MTOR
Atypical CCn1c2c(cc(c1=O)c3ccn[nH]3)c(nc(n2)N)C RGHYDLZMTYDBDT-UHFFFAOYSA-N nan None Achiral Molecule SAR-245409
SAR245409
VOXTALISIB
XL-765
XL765
Belumosudil
4 Surface logix ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
NaN 0.0 452.2 4.8 104.8 6.0 3.0 7.0 On July 2021, FDA approved belumosudil to treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy nan (*) CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5 GKHIVNAUVKXIIY-UHFFFAOYSA-N 2021 None Achiral Molecule KD-025
SLX-2119
Y
Gedatolisib
2 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'VL1' 7jwe nan 1.0 615.3 3.0 128.3 10.0 2.0 7.0 nan PIK3CA
PIK3CB
PIK3CG
PIK3CD
MTOR
Atypical CN(C)C1CCN(CC1)C(=O)c2ccc(cc2)NC(=O)Nc3ccc(cc3)c4nc(nc(n4)N5CCOCC5)N6CCOCC6 DWZAEMINVBZMHQ-UHFFFAOYSA-N nan None Achiral Molecule GEDATOLISIB
PF-05212384
PKI-587
Galunisertib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 369.2 3.5 86.7 5.0 1.0 3.0 nan TGFBR1 TKL Cc1cccc(n1)c2c(c3n(n2)CCC3)c4ccnc5c4cc(cc5)C(=O)N IVRXNBXKWIJUQB-UHFFFAOYSA-N nan None Achiral Molecule GALUNISERTIB
LY-2157299
LY2157299
Tozasertib
2 Merck ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'VX6' 2f4j 2xyn 3amb 3e5a 4af3 4b8m 4jbq 4zog 5wnm 6brj 6gr9 1 0.0 464.2 3.5 102.1 8.0 3.0 7.0 nan AURKA
AURKB
AURKC
Other Cc1cc(n[nH]1)Nc2cc(nc(n2)Sc3ccc(cc3)NC(=O)C4CC4)N5CCN(CC5)C GCIKSSRWRFVXBI-UHFFFAOYSA-N nan None Achiral Molecule MK-045
MK-0457
TOZASERTIB
VX-68
VX-680
Selonsertib
2 Gilead Sciences ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'NJV' 6oyt nan 0.0 445.2 4.7 90.5 7.0 1.0 6.0 nan MAP3K5 STE Cc1cc(c(cc1n2cc(nc2)C3CC3)C(=O)Nc4cccc(n4)c5nncn5C(C)C)F YIDDLAAKOYYGJG-UHFFFAOYSA-N nan None Achiral Molecule GS-4997
SELONSERTIB
Spebrutinib
2 Celgene ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 423.2 4.3 97.4 7.0 3.0 10.0 nan BTK Tyr COCCOc1ccc(cc1)Nc2ncc(c(n2)Nc3cccc(c3)NC(=O)C=C)F KXBDTLQSDKGAEB-UHFFFAOYSA-N nan None Achiral Molecule AVL-292
CC-292
SPEBRUTINIB
Glesatinib
2 Mirati Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
nan 2.0 619.2 6.2 97.4 8.0 3.0 11.0 nan MET
TEK
FLT1
KDR
FLT4
MST1R
Tyr COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=S)NC(=O)Cc5ccc(cc5)F YRCHYHRCBXNYNU-UHFFFAOYSA-N nan None Achiral Molecule GLESATINIB
MG-90265
MG-90265X
MG90265
MG90265GLY
MG90265H9
MG90265X
MGCD-265
MGCD265
Ilorasertib
ABT-348, A-968660;Abt-348, a-968660 2 Abbott Laboratories ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 488.1 5.2 118.1 7.0 4.0 6.0 nan AURKA
AURKB
AURKC
FLT1
PDGFRA
PDGFRB
Other
Tyr
c1cc(cc(c1)F)NC(=O)Nc2ccc(cc2)c3csc4c3c(ncc4c5cnn(c5)CCO)N WPHKIQPVPYJNAX-UHFFFAOYSA-N nan None Achiral Molecule A-968660
A-968660.0
ABBOTT-968660
ABT-348
ABT-348, A-968660
ILORASERTIB
Merestinib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'L1X' 4eev 7aay 2 2.0 552.2 5.7 106.8 7.0 2.0 6.0 nan MET Tyr Cc1ccc(c(=O)n1c2ccc(cc2)F)C(=O)Nc3ccc(c(c3)F)Oc4cc5cnn(c5cc4c6c[nH]nc6)C QHADVLVFMKEIIP-UHFFFAOYSA-N nan None Achiral Molecule LY-2801653
LY2801653
MERESTINIB
Milciclib
2 Nerviano Medical Sciences ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'P48' 2wih 5vc6 5vd1 1 0.0 460.3 2.6 91.2 8.0 2.0 4.0 nan CDK1
NTRK1
CMGC
Tyr
CC1(Cc2cnc(nc2-c3c1c(nn3C)C(=O)NC)Nc4ccc(cc4)N5CCN(CC5)C)C RXZMYLDMFYNEIM-UHFFFAOYSA-N nan None Achiral Molecule MILCICLIB
PHA 848125
PHA-848125
Golvatinib
2 Eisai ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'GV0' 5ia5 2 1.0 633.3 4.8 119.1 7.0 3.0 8.0 nan MET
KDR
Tyr CN1CCN(CC1)C2CCN(CC2)C(=O)Nc3cc(ccn3)Oc4ccc(c(c4)F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F UQRCJCNVNUFYDX-UHFFFAOYSA-N nan None Achiral Molecule E-7050
E7050
GOLVATINIB
Sonolisib
2 Cascadian Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 1.0 525.2 3.1 119.4 9.0 1.0 8.0 nan PIK3CA
PIK3CB
PIK3CG
Atypical CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C/N(CC=C)CC=C)/C4=C(C3=O)O)COC)C)C QIUASFSNWYMDFS-NILGECQDSA-N nan None Single Stereoisomer PX-866
SONOLISIB
Neflamapimod
2 EIP Pharma ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'52P' 3fc1 3hp5 3zsi nan 1.0 435.0 5.5 47.3 5.0 0.0 3.0 nan MAPK14 CMGC c1cc(c(c(c1)Cl)c2c3ccc(nn3cnc2=O)Sc4ccc(cc4F)F)Cl VEPKQEUBKLEPRA-UHFFFAOYSA-N nan None Achiral Molecule 745
NEFLAMAPIMOD
VD-31
VD-31,745
VD-31745
VRT-031745
VX-745
Bentamapimod
2 PregLem ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
FDA SRS
nan 0.0 457.2 4.2 84.2 8.0 0.0 7.0 nan MAPK8
MAPK9
CMGC N#CC(c1nc2ccccc2s1)c5nc(OCc3ccc(cc3)CN4CCOCC4)ncc5 XCPPIJCBCWUBNT-UHFFFAOYSA-N nan None Racemic Mixture AS-602801
BENTAMAPIMOD
PGL-5001
Telatinib
2 Bayer ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 409.1 4.0 102.2 7.0 2.0 6.0 nan KDR
FLT4
Tyr CNC(=O)c1cc(ccn1)COc2c3c(cco3)c(nn2)Nc4ccc(cc4)Cl QFCXANHHBCGMAS-UHFFFAOYSA-N nan None Achiral Molecule BAY 57-9352
BAY-57-9352
BAY-579352
TELATINIB
Rabusertib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 435.1 2.9 97.4 6.0 3.0 5.0 nan CHEK1 CAMK Cc1cc(c(cc1Br)NC(=O)Nc2cnc(cn2)C)OC[C@@H]3CNCCO3 SYYBDNPGDKKJDU-ZDUSSCGKSA-N nan None Single Stereoisomer IC-83
LY-2603618
LY2603618
RABUSERTIB
Adavosertib
2 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'8X7' 5v5y 5vd0 5vdk 1 1.0 500.3 2.9 104.3 10.0 2.0 7.0 nan WEE1 Other CC(C)(c1cccc(n1)n2c3c(cnc(n3)Nc4ccc(cc4)N5CCN(CC5)C)c(=O)n2CC=C)O BKWJAKQVGHWELA-UHFFFAOYSA-N nan None Achiral Molecule ADAVOSERTIB
AZD 1775
AZD-1775
AZD1775
MK-1775
MK1775
Afuresertib
2 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 426.0 3.9 72.9 5.0 2.0 6.0 nan AKT1
AKT2
AKT3
AGC Cn1c(c(cn1)Cl)c2cc(sc2Cl)C(=O)N[C@@H](Cc3cccc(c3)F)CN AFJRDFWMXUECEW-LBPRGKRZSA-N nan None Single Stereoisomer AFURESERTIB
ASB-183
ASB183
GSK-2110183
GSK-2110183C
GSK2110183
GSK2110183C
Delgocitinib
2 Japan Tobacco ChemSpider
ChEMBL
PubChem
BindingDB
nan 0.0 310.2 1.3 88.9 5.0 1.0 2.0 nan nan CC1CN(C12CCN(C2)c3c4cc[nH]c4ncn3)C(=O)CC#N LOWWYYZBZNSPDT-UHFFFAOYSA-N nan None Single Stereoisomer
Tanzisertib
2 Celgene ChemSpider
ChEMBL
DrugBank
RCSB
PDBe
ZINC
FDA SRS
BindingDB
'KBI' 3tti 1 0.0 448.2 3.7 97.1 8.0 3.0 5.0 nan MAPK8 CMGC c1c(c(c(cc1F)F)Nc2n(c3nc(ncc3n2)N[C@H]4CC[C@@H](CC4)O)[C@@H]5COCC5)F IBGLGMOPHJQDJB-IHRRRGAJSA-N nan None Single Stereoisomer CC-930
JNK 930
JNK-930
TANZISERTIB
Amcasertib
2 Boston Biomedical ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
nan 2.0 539.2 6.0 90.1 5.0 3.0 9.0 nan PDGFRA Tyr CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)c4csc(n4)c5ccccc5)C QDWKGEFGLQMDAM-ULJHMMPZSA-N nan None Achiral Molecule AMCASERTIB
BBI-503
BBI503
Amuvatinib
2 Supergen ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 447.1 3.3 75.9 7.0 1.0 3.0

Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical comp\nonent of double-stranded DNA repair in cancer cells.

KIT
MET
RET
FLT3
PDGFRB
Tyr c1ccc2c(c1)c3c(o2)c(ncn3)N4CCN(CC4)C(=S)NCc5ccc6c(c5)OCO6 FOFDIMHVKGYHRU-UHFFFAOYSA-N nan None Achiral Molecule AMUVATINIB
HPK 56
HPK-56
HPK56
MP 470
MP-470
MP470
Gandotinib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 0.0 469.2 4.0 83.4 7.0 2.0 6.0 nan JAK2 Tyr Cc1cc(n[nH]1)Nc2cc(c3nc(c(n3n2)Cc4ccc(cc4F)Cl)C)CN5CCOCC5 SQSZANZGUXWJEA-UHFFFAOYSA-N nan None Achiral Molecule GANDOTINIB
LY-2784544
LY2784544
Bafetinib
2 Innovive Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'406' 2e2b 2 2.0 576.3 5.4 99.2 8.0 2.0 8.0 nan LYN
ABL1
Tyr Cc1ccc(cc1Nc2nccc(n2)c3cncnc3)NC(=O)c4ccc(c(c4)C(F)(F)F)CN5CC[C@@H](C5)N(C)C ZGBAJMQHJDFTQJ-DEOSSOPVSA-N nan None Single Stereoisomer BAFETINIB
CNS-9
INNO-406
NS-187
Belvarafenib
2 Hanmi Pharmaceutical ChemSpider
ChEMBL
PubChem
RCSB
PDBe
FDA SRS
BindingDB
'V1Y' 6xfp nan 1.0 478.1 5.9 105.8 7.0 3.0 4.0 nan nan CC1=C(C2=C(C=C1)C(=NC=C2)NC3=C(C(=CC=C3)Cl)F)NC(=O)C4=CSC5=C4N=CN=C5N KVCQTKNUUQOELD-UHFFFAOYSA-N nan NaN NaN BELVARAFENIB
Onatasertib
2 Celgene ChemSpider
ChEMBL
DrugBank
ZINC
FDA SRS
BindingDB
nan 0.0 397.2 2.5 100.5 7.0 2.0 4.0 nan nan CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1 UFKLYTOEMRFKAD-SHTZXODSSA-N nan None Single Stereoisomer ATG-008
CC-223
ONATASERTIB
Mirdametinib
2 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'4BM' 3eqg 3vvh 7juu 7jv0 7m0x nan 0.0 482.0 2.5 90.8 5.0 4.0 7.0 nan nan O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F SUDAHWBOROXANE-SECBINFHSA-N nan None Single Stereoisomer MIRDAMETINIB
PD 0325901
PD-0325901
Tamatinib
2 Rigel Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'585' 3fqs 3piy 1 0.0 470.2 3.6 128.8 10.0 3.0 7.0 nan SYK Tyr CC1(C(=O)Nc2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)C NHHQJBCNYHBUSI-UHFFFAOYSA-N nan NaN NaN R-406
Roniciclib
2 Bayer ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB
nan 0.0 430.1 4.0 108.2 7.0 3.0 7.0 nan CDK1
CDK2
CDK4
CDK9
CMGC C[C@H]([C@@H](C)Oc1c(cnc(n1)Nc2ccc(cc2)[S@](=N)(=O)C3CC3)C(F)(F)F)O UELYDGOOJPRWGF-SRQXXRKNSA-N nan None Single Stereoisomer
Vorolanib
2 Tyrogenex ChemSpider
ChEMBL
PubChem
DrugBank
FDA SRS
nan 0.0 439.2 2.7 97.5 3.0 3.0 3.0 nan nan Cc1c([nH]c(c1C(=O)N[C@H]2CCN(C2)C(=O)N(C)C)C)/C=C\3/c4cc(ccc4NC3=O)F KMIOJWCYOHBUJS-HAKPAVFJSA-N nan None Single Stereoisomer VOROLANIB
Zorifertinib
2 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 459.1 4.3 79.8 7.0 1.0 4.0 nan nan COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C MXDSJQHFFDGFDK-CYBMUJFWSA-N nan None Single Stereoisomer AZD 3759
AZD-3759
AZD3759
ZORIFERTINIB
Pelitinib
2 Wyeth ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'93J' 5vcw 7axm 1 1.0 467.2 5.1 90.3 6.0 2.0 8.0 nan EGFR
ERBB2
Tyr CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)F WVUNYSQLFKLYNI-AATRIKPKSA-N nan None Achiral Molecule EKB-569
PELITINIB
WAY-EKB-569
Pilaralisib
2 Sanofi ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB
nan 1.0 540.1 4.5 148.3 8.0 4.0 8.0 nan PIK3CA
PIK3CB
PIK3CD
PIK3CG
Atypical CC(C)(C(=O)Nc1cccc(c1)S(=O)(=O)Nc2c(nc3ccccc3n2)Nc4cc(ccc4Cl)OC)N QINPEPAQOBZPOF-UHFFFAOYSA-N nan None Achiral Molecule PILARALISIB
SAR-245408
SAR245408
XL-147
XL147
Verosudil
2 Aerie Pharmaceutical ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
FDA SRS
nan 0.0 327.1 2.8 65.2 4.0 2.0 4.0 nan nan CN(C)C(c1ccsc1)C(=O)Nc2ccc3c(c2)cc[nH]c3=O VDYRZXYYQMMFJW-UHFFFAOYSA-N nan None Racemic Mixture AR-12286
AR-12286 FREE BASE
VEROSUDIL
Poziotinib
2 Hanmi Pharmaceutical ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 490.1 5.4 76.6 6.0 1.0 6.0 nan EGFR Tyr COc1cc2c(cc1OC3CCN(CC3)C(=O)C=C)c(ncn2)Nc4ccc(c(c4F)Cl)Cl LPFWVDIFUFFKJU-UHFFFAOYSA-N nan None Achiral Molecule HM 781-36
HM 781-36B
HM-781-36
HM-781-36B
NOV-120101
POZIOTINIB
Pictilisib
2 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'GD9' 2wxp 2y3a 3dbs 1 1.0 513.2 2.1 107.6 9.0 1.0 5.0 nan PIK3CA
PIK3CB
PIK3CD
PIK3CG
Atypical CS(=O)(=O)N1CCN(CC1)Cc2cc3c(s2)c(nc(n3)c4cccc5c4cn[nH]5)N6CCOCC6 LHNIIDJUOCFXAP-UHFFFAOYSA-N nan None Achiral Molecule CDC-0941
GDC 0941
GDC-0941
PICTILISIB
RG-7321
Ripasudil
2 Kowa Pharmaceutical ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 323.1 1.7 62.3 4.0 1.0 2.0 nan nan C[C@H]1CNCCCN1S(=O)(=O)c2cccc3c2c(cnc3)F QSKQVZWVLOIIEV-NSHDSACASA-N nan None Single Stereoisomer RIPASUDIL
Olmutinib
2 Hanmi Pharmaceutical ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 486.2 5.1 82.6 8.0 2.0 7.0 For use in treatment of metastatic T790M mutation positive non-small cell lung cancer EGFR Tyr CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccsc4c(n3)Oc5cccc(c5)NC(=O)C=C FDMQDKQUTRLUBU-UHFFFAOYSA-N nan None Achiral Molecule BI 1482694
BI-1482694
HM-61713
HM61713
OLMUTINIB
Prexasertib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 365.2 2.2 134.8 8.0 3.0 8.0 nan CHEK1
CHEK2
CAMK COc1cccc(c1c2cc(n[nH]2)Nc3cnc(cn3)C#N)OCCCN DOTGPNHGTYJDEP-UHFFFAOYSA-N nan None Achiral Molecule LY2606368
PREXASERTIB
Vactosertib
2 MedPacto ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 399.2 4.2 83.8 6.0 2.0 5.0

Vactosertib (EW-7197) acts as in inhibitor of transforming growth factor beta receptor 1B (ALK5) and activin A receptor type IB (ALK4). The compound is potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity.

nan Cc1cccc(n1)c2c(nc([nH]2)CNc3ccccc3F)c4ccc5ncnn5c4 FJCDSQATIJKQKA-UHFFFAOYSA-N nan None Achiral Molecule TEW 7197
TEW-7197
VACTOSERTIB
Ralimetinib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 1.0 420.2 5.6 85.4 5.0 2.0 3.0 nan MAPK14
MAPK11
CMGC CC(C)(C)Cn1c2c(ccc(n2)c3c(nc([nH]3)C(C)(C)C)c4ccc(cc4)F)nc1N XPPBBJCBDOEXDN-UHFFFAOYSA-N nan None Achiral Molecule LSN-2322600 FREE BASE
LSN2322600 FREE BASE
LY-2228820
LY2228820
LY22288220
RALIMETINIB
Acumapimod
2 Mereo BioPharma ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 0.0 385.2 2.8 113.8 6.0 2.0 5.0 nan MAPK14
MAPK11
MAPK13
MAPK12
CMGC Cc1ccc(cc1n2c(c(cn2)C(=O)c3cccc(c3)C#N)N)C(=O)NC4CC4 VGUSQKZDZHAAEE-UHFFFAOYSA-N nan None Single Stereoisomer
Paxalisib
2 Genentech ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 382.2 1.0 117.1 10.0 1.0 2.0 nan nan CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12 LGWACEZVCMBSKW-UHFFFAOYSA-N nan None Achiral Molecule G-02441729
G02441729
GDC-0084
GDC0084
PAXALISIB
RG-7666
Refametinib
2 Bayer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
'VRA' 3e8n nan 1.0 572.0 3.5 107.9 6.0 4.0 9.0 nan MAP2K1 STE COc1cc(c(c(c1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)Nc3ccc(cc3F)I)F)F RDSACQWTXKSHJT-NSHDSACASA-N nan None Single Stereoisomer BAY 869766
BAY 8697661
BAY-86-9766
BAY-869766
BAY-8697661
BAY86-9766
RDEA 119
RDEA-119
REFAMETINIB
Simurosertib
2 Takeda ChemSpider
PubChem
nan 0.0 341.1 2.8 77.7 5.0 2.0 2.0 nan nan Cc1c(c[nH]n1)c2cc3c(s2)c(=O)[nH]c(n3)C4CC5CCN4CC5 XGVXKJKTISMIOW-UHFFFAOYSA-N nan None Single Stereoisomer
TAK-931
Talmapimod
2 Scios inc ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'469' 3hub 3zsh 1 1.0 512.2 4.0 65.9 5.0 0.0 5.0 Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis. MAPK14 CMGC C[C@@H]1CN([C@H](CN1C(=O)c2cc3c(cc2Cl)n(cc3C(=O)C(=O)N(C)C)C)C)Cc4ccc(cc4)F ZMELOYOKMZBMRB-DLBZAZTESA-N nan None Single Stereoisomer SCIO 469
SCIO-469
TALMAPIMOD
Parsaclisib
2 Incyte Corporation ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 432.1 3.1 107.9 7.0 2.0 5.0

Parsaclisib (INCB050465) is a PI3Kδ inhibitor that was developed by Incyte Corporation as an antineoplastic and immunomodulatory agent, as claimed in their patent WO2014134426A1 [1]. The chemical structure is one of those claimed in patent WO2013033569A1, but it is not clear which example it is from a mixture of diastereoisomers 345-348 (although 347 and 348 had the highest inhibitory potency vs. PI3Kδ and 347 was tested in vivo [2].

nan CCOc1c(cc(c(c1[C@H]2CC(=O)NC2)F)Cl)[C@H](C)n3c4c(c(n3)C)c(ncn4)N ZQPDJCIXJHUERQ-QWRGUYRKSA-N nan None Single Stereoisomer INCB-050465
INCB050465
PARSACLISIB
Nemiralisib
2 GlaxosmithKline ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'VVX' 5ae8 nan 0.0 440.2 4.9 77.0 5.0 2.0 5.0 nan nan CC(C)N1CCN(CC1)Cc2cnc(o2)c3cc(cc4c3cn[nH]4)c5cccc6c5cc[nH]6 MCIDWGZGWVSZMK-UHFFFAOYSA-N nan None Achiral Molecule GSK-2269557
GSK-2269557 FREE BASE
GSK-2269557A
GSK2269557A
NEMIRALISIB
Doramapimod
2 Boehringer Ingelheim ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'B96' 1kv2 3fzs 3npc 4jvg 4twn 5n66 6gtt 2 2.0 527.3 6.0 80.7 6.0 2.0 7.0 nan MAPK14 CMGC Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)Nc3ccc(c4c3cccc4)OCCN5CCOCC5 MVCOAUNKQVWQHZ-UHFFFAOYSA-N nan None Achiral Molecule BIRB 796 BS
BIRB-796
BIRB-796 BS
DORAMAPIMOD
Solcitinib
2 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 389.2 3.2 79.6 5.0 1.0 4.0 nan JAK1 Tyr CC1(CN(C1)C(=O)c2ccc(cc2)c3cccc4n3nc(n4)NC(=O)C5CC5)C MPYACSQFXVMWNO-UHFFFAOYSA-N nan None Achiral Molecule G-154578
G154578
GLPG-0778
GLPG-0788
GLPG0778
GSK-2586184
GSK-2586184A
GSK2586184A
SOLCITINIB
Tirabrutinib
2 Ono Pharmaceutical ChemSpider
PubChem
nan 0.0 454.2 2.8 108.3 8.0 1.0 4.0 nan nan CC#CC(=O)N1CCC(C1)n2c3c(c(ncn3)N)n(c2=O)c4ccc(cc4)Oc5ccccc5 SEJLPXCPMNSRAM-UHFFFAOYSA-N nan None Single Stereoisomer
GS-4059
ONO-4059(FREE BASE)
ONO-4059
Rebastinib
DP-1919;Dp-1919 2 Deciphera Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'919' 3qri 3qrj 5g6v 6cnh 6mwe 2 2.0 553.2 6.0 123.1 7.0 3.0 6.0 nan FLT3
TEK
KDR
LYN
BCR
ABL1
NTRK1
Atypical
Tyr
CC(C)(C)c1cc(n(n1)c2ccc3c(c2)cccn3)NC(=O)Nc4ccc(cc4F)Oc5ccnc(c5)C(=O)NC WVXNSAVVKYZVOE-UHFFFAOYSA-N nan None Achiral Molecule DCC-2036
DCC-2036 FREE BASE
DP-1919
REBASTINIB
Danusertib
2 Nerviano Medical Sciences ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'627' 2j50 2v7a 4qo9 5i9z 1 0.0 474.2 2.6 93.8 6.0 2.0 6.0 nan AURKA
AURKB
AURKC
Other CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3c4c([nH]n3)CN(C4)C(=O)[C@@H](c5ccccc5)OC XKFTZKGMDDZMJI-HSZRJFAPSA-N nan None Single Stereoisomer DANUSERTIB
PHA-739358
Pimasertib
as703026; emd 1036239;AS703026;EMD 1036239;MSC1936369A;Msc1936369a;Msc1936369a; as703026; emd 1036239;as703026 2 Merck ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'QOA' 7m0w nan 0.0 431.0 1.7 94.5 5.0 4.0 6.0 nan MAP2K1
MAP2K2
STE c1cc(c(cc1I)F)Nc2cnccc2C(=O)NC[C@@H](CO)O VIUAUNHCRHHYNE-JTQLQIEISA-N nan None Single Stereoisomer AS 703026
AS-703026
AS703026
EMD 1036239
EMD-1036239
G-02443714
MSC-1936369A
MSC-1936369B
MSC1936369A
MSC1936369A; AS703026; EMD 1036239
PIMASERTIB
Vodobatinib
2 Sun Pharma Advanced Research Company ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
FDA SRS
nan 0.0 453.1 5.0 71.1 3.0 2.0 2.0 nan nan Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1 ZQOBVMHBVWNVBG-UHFFFAOYSA-N nan None Achiral Molecule K0706
VODOBATINIB
Tenalisib
2 Rhizen Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 415.1 4.8 96.7 6.0 2.0 5.0 nan nan CC[C@@H](c1c(c(=O)c2ccccc2o1)c3cccc(c3)F)Nc4c5c([nH]cn5)ncn4 HDXDQPRPFRKGKZ-INIZCTEOSA-N nan None Single Stereoisomer TENALISIB
Vistusertib
2 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 462.2 2.5 92.7 8.0 1.0 4.0 nan MTOR Atypical C[C@H]1COCCN1c2c3ccc(nc3nc(n2)N4CCOC[C@@H]4C)c5cccc(c5)C(=O)NC JUSFANSTBFGBAF-IRXDYDNUSA-N nan None Single Stereoisomer AZD-2014
AZD2014
VISTUSERTIB
Tandutinib
2 Takeda ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB
nan 2.0 562.3 5.0 92.3 8.0 1.0 10.0 Investigated for use/treatment in leukemia (myeloid). FLT3
PDGFD
(*)
Tyr
CC(C)Oc1ccc(cc1)NC(=O)N2CCN(CC2)c3c4cc(c(cc4ncn3)OCCCN5CCCCC5)OC UXXQOJXBIDBUAC-UHFFFAOYSA-N nan None Achiral Molecule CT 53518
CT-53518
CT53518
MLN-0518
MLN-518
TANDUTINIB
Rogaratinib
2 Bayer ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 466.2 2.6 107.0 9.0 2.0 6.0 Rogaratinib (BAY-1163877) is a FGFR-selective kinase inhibitor that is being investigated for antineoplastic activity. nan Cc1cc2cc(sc2c(c1)OC)c3c(c(n4c3c(ncn4)N)CN5CCNC(=O)C5)COC HNLRRJSKGXOYNO-UHFFFAOYSA-N nan None Achiral Molecule BAY-1163877
ROGARATINIB
Pamapimod
2 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'FLW' 3flw 1 0.0 406.1 1.9 109.5 8.0 3.0 8.0 nan MAPK14
MAPK11
CMGC Cn1c2c(cc(c1=O)Oc3ccc(cc3F)F)cnc(n2)NC(CCO)CCO JYYLVUFNAHSSFE-UHFFFAOYSA-N nan None Achiral Molecule PAMAPIMOD
R-1503
R1503
RO 4402257
RO-4402257
Foslinanib
2 TaiRx ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
nan 0.0 365.0 2.8 108.8 4.0 3.0 4.0 nan nan COc1ccc2c(c1OP(=O)(O)O)c(=O)cc([nH]2)c3cccc(c3)F ZDWFMAHQGDEALT-UHFFFAOYSA-N nan None Achiral Molecule CVM-1118
CVM-1118 FREE ACID
FOSLINANIB
TRX 818
TRX-818
TRX-818 FREE ACID
Seletalisib
2 UCB ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 482.1 5.2 90.5 6.0 1.0 4.0 nan nan c1cc2cc(c(nc2c(c1)Cl)c3ccc[n+](c3)[O-])[C@H](C(F)(F)F)Nc4c5c(cccn5)ncn4 LNLJHGXOFYUARS-OAQYLSRUSA-N nan None Single Stereoisomer SELETALISIB
UCB-5857
UCB5857
Seliciclib
2 Cyclacel pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'RRC' 1unl 1ygk 2a4l 3ddq 1 0.0 354.2 3.2 87.9 7.0 3.0 8.0 nan CDK2
CDK7
CDK9
CMGC CC[C@H](CO)Nc1nc(NCc2ccccc2)c3ncn(C(C)C)c3n1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N nan None Single Stereoisomer AL-39256
CYC-202
NSC-701554
SELICICLIB
Sapanisertib
2 Takeda ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'FE5' 6gvf nan 0.0 309.1 2.4 121.7 8.0 2.0 2.0 nan MTOR Atypical CC(C)n1c2c(c(n1)c3ccc4c(c3)nc(o4)N)c(ncn2)N GYLDXIAOMVERTK-UHFFFAOYSA-N nan None Achiral Molecule INK-128
INK128
MLN-0128
MLN0128
SAPANISERTIB
TAK-228
Samotolisib
2 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 0.0 406.2 3.2 82.2 7.0 1.0 5.0

LY3023414 is a dual inhibitor of phosphoinositide 3-kinase α (PI3Kα) and the serine/threonine kinase mTOR (mechanistic target of rapamycin), with potential antineoplastic activity.

nan C[C@@H](Cn1c2c3cc(ccc3ncc2n(c1=O)C)c4cc(cnc4)C(C)(C)O)OC ACCFLVVUVBJNGT-AWEZNQCLSA-N nan None Single Stereoisomer LY 3023414
LY-3023414
LY3023414
SAMOTOLISIB
Fenebrutinib
2 Genentech ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'9AJ' 5vfi nan 2.0 664.3 3.6 121.0 11.0 2.0 7.0 nan nan C[C@H]1CN(CCN1c2ccc(nc2)Nc3cc(cn(c3=O)C)c4ccnc(c4CO)N5CCn6c(cc7c6CC(C7)(C)C)C5=O)C8COC8 WNEODWDFDXWOLU-QHCPKHFHSA-N nan None Single Stereoisomer FENEBRUTINIB
G-02599853
G02599853
GDC-0853
RG-7845
RG7845
RO-7010939
RO7010939
Ulixertinib
2 BioMed Valley Discoveries ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
'EVK' 6gdq nan 0.0 432.1 4.7 90.0 4.0 4.0 7.0 nan MAPK1
MAPK3
CMGC CC(C)Nc1cc(c(cn1)Cl)c2cc([nH]c2)C(=O)N[C@H](CO)c3cccc(c3)Cl KSERXGMCDHOLSS-LJQANCHMSA-N nan None Single Stereoisomer BVD-523
BVD-ERK
ULIXERTINIB
VRT-752271
Sotrastaurin
2 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'LW4' 3iw4 nan 0.0 438.2 2.4 94.2 6.0 2.0 3.0 nan nan CN1CCN(CC1)c2nc3ccccc3c(n2)C4=C(C(=O)NC4=O)c5c[nH]c6c5cccc6 OAVGBZOFDPFGPJ-UHFFFAOYSA-N nan None Achiral Molecule AEB-071
AEB071
NVP-AEB071
SOTRASTAURIN
Uprosertib
2 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 428.1 3.6 86.1 5.0 2.0 6.0 nan AKT1
AKT2
AKT3
AGC Cn1c(c(cn1)Cl)c2cc(oc2Cl)C(=O)N[C@@H](Cc3ccc(c(c3)F)F)CN AXTAPYRUEKNRBA-JTQLQIEISA-N nan None Single Stereoisomer GSK-2141795
GSK-2141795C
GSK2141795
GSK2141795C
UPROSERTIB
Voruciclib
2 Piramal Enterprises ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 469.1 4.3 94.1 6.0 3.0 3.0 nan CDK4 CMGC CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccc(cc4Cl)C(F)(F)F)O)O MRPGRAKIAJJGMM-OCCSQVGLSA-N nan None Single Stereoisomer P1446A-05
VORUCICLIB
Edicotinib
2 Janssen ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 461.3 6.0 103.7 5.0 2.0 4.0 nan nan CC1(CCC(=CC1)c2c(ccc(n2)C3CC(OC(C3)(C)C)(C)C)NC(=O)c4[nH]c(cn4)C#N)C BNVPFDRNGHMRJS-UHFFFAOYSA-N nan None Achiral Molecule EDICOTINIB
JNJ-40346527
Decernotinib
2 Vertex Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'VJK' 4yti 1 0.0 392.2 3.3 95.6 5.0 3.0 6.0 nan JAK3 Tyr CC[C@](C)(C(=O)NCC(F)(F)F)Nc1ccnc(n1)c2c[nH]c3c2cccn3 ASUGUQWIHMTFJL-QGZVFWFLSA-N nan None Single Stereoisomer ADELATINIB
DECERNOTINIB
VRT-831509
VX-509
Chiauranib
2 Chipscreen Biosciences ChemSpider
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
nan 1.0 435.2 6.0 86.5 5.0 2.0 5.0 nan nan COC1=CC=C2C(=CC=NC2=C1)OC1=CC2=CC=CC(C(=O)NC3=CC=CC=C3N)=C2C=C1 BRKWREZNORONDU-UHFFFAOYSA-N nan None Single Stereoisomer
CS2164
CS-2164
Sapitinib
2 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 473.2 3.8 88.6 7.0 2.0 7.0 nan EGFR
ERBB2
ERBB4
ERBB3
Tyr CNC(=O)CN1CCC(CC1)Oc2cc3c(cc2OC)ncnc3Nc4cccc(c4F)Cl DFJSJLGUIXFDJP-UHFFFAOYSA-N nan None Achiral Molecule AZD-8931
AZD8931
SAPITINIB
Allitinib
2 Allist Pharmaceuticals ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
nan 1.0 448.1 5.9 76.1 5.0 2.0 7.0 nan ERBB2
EGFR
Tyr C=CC(=O)Nc1ccc2c(c1)c(ncn2)Nc3ccc(c(c3)Cl)OCc4cccc(c4)F MVZGYPSXNDCANY-UHFFFAOYSA-N nan None Single Stereoisomer ALL-3
ALLITINIB
AST-1306
Ilginatinib
2 Nippon Shinyaku ChemSpider
PubChem
nan 0.0 389.2 4.3 80.6 7.0 2.0 6.0 nan nan CC(c1ccc(cc1)F)Nc2cc(cc(n2)Nc3cnccn3)c4cnn(c4)C UQTPDWDAYHAZNT-UHFFFAOYSA-N nan None Single Stereoisomer
NS-018
Serabelisib
2 Takeda ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 363.1 2.2 98.9 7.0 1.0 2.0 nan nan c1cc2c(cc1c3ccc4ncc(n4c3)C(=O)N5CCOCC5)nc(o2)N BLGWHBSBBJNKJO-UHFFFAOYSA-N nan None Achiral Molecule AGN-PC-0DB6FL
INK1117
MLN-1117
MLN1117
SERABELISIB
TAK-117
Ifidancitinib
2 Rigel Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
NaN 0.0 395.1 4.2 105.1 7.0 3.0 5.0 nan (*) COc1cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc(C)c1F OYFMQDVLFYKOPZ-UHFFFAOYSA-N NaN None Achiral Molecule A-301
ATI-502
IFIDANCITINIB
Onvansertib
2 Cardiff Oncology ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'937' 2yac nan 1.0 532.2 1.9 134.7 10.0 3.0 7.0 nan nan CN1CCN(CC1)c2ccc(c(c2)Nc3ncc4c(n3)-c5c(c(nn5CCO)C(=O)N)CC4)OC(F)(F)F QHLVBNKYJGBCQJ-UHFFFAOYSA-N nan None Achiral Molecule NMS-1286937
NMS-P937
ONVANSERTIB
PCM-075
Acalisib
2 Gilead Sciences ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 401.1 3.4 101.4 7.0 2.0 4.0 nan PIK3CA Atypical C[C@@H](c1nc2ccc(cc2c(=O)n1c3ccccc3)F)Nc4c5c(nc[nH]5)ncn4 DOCINCLJNAXZQF-LBPRGKRZSA-N nan None Single Stereoisomer
Gusacitinib
2 Asana BioSciences ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
nan 0.0 460.2 2.5 134.1 9.0 3.0 5.0 nan nan N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1 NLFLXLJXEIUQDL-UHFFFAOYSA-N nan None Achiral Molecule ASN-002
ASN002
EN-3351
EN3351
GUSACITINIB
Opaganib
2.5 RedHill Biopharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 380.2 4.9 42.0 2.0 1.0 4.0 nan nan c1cc(ccc1C23CC4CC(C2)CC(C4)(C3)C(=O)NCc5ccncc5)Cl CAOTVXGYTWCKQE-UHFFFAOYSA-N nan None Achiral Molecule ABC 294640
ABC-294640
OPAGANIB
Varlitinib
2.5 Array Biopharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 466.1 5.2 93.5 9.0 2.0 6.0 Investigated for use/treatment in cancer/tumors (unspecified). EGFR
ERBB2
Tyr C[C@@H]1COC(=N1)Nc2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5nccs5 UWXSAYUXVSFDBQ-CYBMUJFWSA-N nan None Single Stereoisomer AR-00334543
ARRY-334543
ARRY-543
ASLAN-001
ASLAN001
VARLITINIB
Inavolisib
2.5 Genentech ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 407.1 2.9 112.7 7.0 3.0 5.0 nan nan C[C@@H](C(=N)O)Nc1ccc-2c(c1)OCCn3c2nc(c3)N4[C@@H](COC4=O)C(F)F SGEUNORSOZVTOL-CABZTGNLSA-N nan None Unknown RO7113755
RO7113755, GDC-0077
INAVOLISIB
GDC0077
GDC-0077
RG6114
Cerdulatinib
2.5 Portola pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 445.2 1.4 133.6 8.0 3.0 8.0 nan JAK1
SYK
Tyr CCS(=O)(=O)N1CCN(CC1)c2ccc(cc2)Nc3ncc(c(n3)NC4CC4)C(=O)N BGLPECHZZQDNCD-UHFFFAOYSA-N nan None Single Stereoisomer
Simotinib
3 Advenchen Laboratories ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
nan 1.0 500.2 4.4 78.0 8.0 1.0 7.0 nan EGFR Tyr COc1cc2c(cc1OCCN3CC4(CC4)C5(C3)OCCO5)c(ncn2)Nc6ccc(c(c6)Cl)F OXWUWXCJDBRCCG-UHFFFAOYSA-N nan None Achiral Molecule SIM-6802
SIMOTINIB
Peficitinib
3 Astellas Pharma ChemSpider
ChEMBL
RCSB
PDBe
ZINC
'9T6' 6aah 6aaj 6aak 6aam nan 0.0 326.2 2.0 104.0 4.0 4.0 3.0 nan JAK1
JAK2
JAK3
TYK2
Tyr c1c[nH]c2c1c(c(cn2)C(=O)N)N[C@@H]3[C@@H]4C[C@@H]5C[C@H]3C[C@@](C5)(C4)O DREIJXJRTLTGJC-ZKVNVPQCSA-N nan None Racemic Mixture
Evobrutinib
3 Merck ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'MZJ' 6omu nan 0.0 429.2 4.4 93.4 6.0 2.0 7.0 nan BTK Tyr C=CC(=O)N1CCC(CC1)CNc2c(c(ncn2)N)c3ccc(cc3)Oc4ccccc4 QUIWHXQETADMGN-UHFFFAOYSA-N nan None Achiral Molecule EVOBRUTINIB
M-2951
Pyrotinib
3 Hengrui Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 2.0 582.2 6.5 112.4 8.0 2.0 10.0 nan EGFR
ERBB2
Tyr CCOc1cc2c(cc1NC(=O)/C=C/[C@H]3CCCN3C)c(c(cn2)C#N)Nc4ccc(c(c4)Cl)OCc5ccccn5 SADXACCFNXBCFY-IYNHSRRRSA-N nan None Single Stereoisomer
Quizartinib
3 Ambit Biosciences ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'P30' 4rt7 4xuf 2 2.0 560.2 5.9 106.2 9.0 2.0 7.0 nan FLT3
CSF1R
KIT
Tyr CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6 CVWXJKQAOSCOAB-UHFFFAOYSA-N nan None Achiral Molecule AC-010220
AC-220
AC010220
AC220
ASP-2689
QUIZARTINIB
Radotinib
3 Il-Yang Pharmaceutical ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 2.0 530.2 5.8 110.5 8.0 2.0 6.0

Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.

ABL1
PDGFRB
Tyr Cc1ccc(cc1Nc2nccc(n2)c3cnccn3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F DUPWHXBITIZIKZ-UHFFFAOYSA-N nan None Achiral Molecule IY5511
RADOTINIB
Ensartinib
3 Xcovery ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB
nan 1.0 560.2 4.7 122.5 7.0 3.0 6.0 nan ALK Tyr C[C@@H]1CN(C[C@@H](N1)C)C(=O)c2ccc(cc2)NC(=O)c3cc(c(nn3)N)O[C@H](C)c4c(ccc(c4Cl)F)Cl GLYMPHUVMRFTFV-QLFBSQMISA-N nan None Single Stereoisomer ENSARTINIB
X-396
Famitinib
3 Jiangsu Hengrui Medicine ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 410.2 3.3 68.4 3.0 2.0 6.0 nan KIT
KDR
FLT4
PDGFRA
PDGFRB
FLT1
FLT3
Tyr CCN(CC)CCN1CCc2c(c(c([nH]2)/C=C\3/c4cc(ccc4NC3=O)F)C)C1=O GKEYKDOLBLYGRB-LGMDPLHJSA-N nan None Single Stereoisomer SHR-1020
Rilzabrutinib
3 Principia Biopharma ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
nan 2.0 665.3 4.4 138.7 11.0 1.0 8.0 nan nan CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1 LCFFREMLXLZNHE-GBOLQPHISA-N nan None Single Stereoisomer PRN1008
RILZABRUTINIB
Canertinib
3 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 485.2 4.4 88.6 7.0 2.0 9.0 Investigated for use/treatment in breast cancer and lung cancer. EGFR Tyr C=CC(=O)Nc1cc2c(cc1OCCCN3CCOCC3)ncnc2Nc4ccc(c(c4)Cl)F OMZCMEYTWSXEPZ-UHFFFAOYSA-N nan None Achiral Molecule CANERTINIB
CI-1033
Rociletinib
3 Clovis Oncology ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'8JC' 5xdk 5xdl 1 1.0 555.2 4.8 111.7 8.0 3.0 8.0 nan EGFR Tyr CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F HUFOZJXAKZVRNJ-UHFFFAOYSA-N nan None Achiral Molecule AVL-301
CNX-419
CO-1686
CS-1631
ROCILETINIB
Abrocitinib
3 Pfizer ChemSpider
PubChem
nan 0.0 323.1 1.3 91.0 5.0 2.0 6.0 nan nan CCCS(=O)(=O)NC1CC(C1)N(C)c2c3cc[nH]c3ncn2 IUEWXNHSKRWHDY-UHFFFAOYSA-N nan None Single Stereoisomer
PF-04965842
Masitinib
Kinavet;Masivet 3 AB Science ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'G65' 5mql 7ju7 nan 1.0 498.2 5.3 73.4 7.0 2.0 7.0 nan KIT
PDGFRA
PDGFRB
FGFR1
FGFR2
FGFR3
Tyr Cc1ccc(cc1Nc2nc(cs2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C WJEOLQLKVOPQFV-UHFFFAOYSA-N nan None Achiral Molecule AB-1010
KINAVET
MASITINIB
MASIVET
Savolitinib
3 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'V0L' 5lbw 6sde nan 0.0 345.1 1.9 91.6 9.0 0.0 3.0 nan MET Tyr C[C@@H](c1ccc2nccn2c1)n3c4c(ncc(n4)c5cnn(c5)C)nn3 XYDNMOZJKOGZLS-NSHDSACASA-N nan None Single Stereoisomer AZD-6094
AZD6094
HMPL-504
SAVOLITINIB
VOLITINIB
Pacritinib
3 Cell Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'6T3' 5lbz nan 0.0 472.2 5.0 68.7 7.0 1.0 4.0 nan JAK2 Tyr c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5 HWXVIOGONBBTBY-ONEGZZNKSA-N nan None Achiral Molecule ONX-0803
PACRITINIB
SB-1518
SB1518
Tivantinib
3 Daiichi Sankyo ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'TIV' 5cb4 nan 0.0 369.1 3.6 66.9 3.0 2.0 2.0 nan MET Tyr c1ccc2c(c1)c(c[nH]2)[C@H]3[C@@H](C(=O)NC3=O)c4cn5c6c4cccc6CCC5 UCEQXRCJXIVODC-PMACEKPBSA-N nan None Single Stereoisomer ARQ 197
ARQ-197
TIVANTINIB
Tesevatinib
3 Kadmon Corporation ChemSpider
ChEMBL
DrugBank
ZINC
FDA SRS
BindingDB
nan 1.0 490.1 5.8 59.5 6.0 1.0 6.0 nan EGFR
ERBB2
KDR
FLT4
EPHB4
Tyr CN1C[C@H]2C[C@H](C[C@H]2C1)COc3cc4c(cc3OC)c(ncn4)Nc5ccc(c(c5F)Cl)Cl HVXKQKFEHMGHSL-QKDCVEJESA-N nan None Racemic Mixture EXEL-7647
KD-019
KD-020
KD019
TESEVATINIB
XL-647
XL647
Surufatinib
3 Hutchison MediPharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 0.0 480.2 3.8 112.2 7.0 3.0 10.0 nan nan Cc1cc2cc(ccc2[nH]1)Oc3ccnc(n3)Nc4cccc(c4)CS(=O)(=O)NCCN(C)C TTZSNFLLYPYKIL-UHFFFAOYSA-N nan None Achiral Molecule HMPL-012
SULFATINIB
SURUFATINIB
Saracatinib
3 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'H8H' 2h8h 4qmx 5vcx 5vd3 6zgc 1 1.0 541.2 3.9 90.4 10.0 1.0 8.0 nan SRC
ABL1
Tyr CN1CCN(CC1)CCOc2cc3c(c(c2)OC4CCOCC4)c(ncn3)Nc5c(ccc6c5OCO6)Cl OUKYUETWWIPKQR-UHFFFAOYSA-N nan None Achiral Molecule AZ-10353926
AZD-0530
AZD0530
SARACATINIB
Taselisib
3 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'799' 5t8f 1 0.0 460.2 3.2 118.7 9.0 1.0 5.0 nan PIK3CA
PIK3CD
PIK3CG
Atypical Cc1nc(n(n1)C(C)C)c2cn3c(n2)-c4ccc(cc4OCC3)c5cnn(c5)C(C)(C)C(=O)N BEUQXVWXFDOSAQ-UHFFFAOYSA-N nan None Racemic Mixture GDC-0032
RG-7604
TASELISIB
Ritlecitinib
3 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 285.2 1.9 73.9 4.0 2.0 3.0 nan nan C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C CBRJPFGIXUFMTM-WDEREUQCSA-N nan None Single Stereoisomer PF-06651600
RITLECITINIB
Deucravacitinib
3 Bristol Myers Squibb ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 425.2 1.2 139.2 8.0 3.0 7.0 nan nan C[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC BZZKEPGENYLQSC-FIBGUPNXSA-N nan None Achiral Molecule BMS-986165
DEUCRAVACITINIB
Sitravatinib
3 Mirati Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 2.0 629.2 6.5 114.5 8.0 3.0 12.0 nan RET
DDR2
NTRK1
NTRK2
NTRK3
Tyr COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F WLAVZAAODLTUSW-UHFFFAOYSA-N nan None Achiral Molecule MG-516
MG-91516
MGCD-516
MGCD516
SITRAVATINIB
Semaxanib
3 Sugen ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'X2M' 2x2m 1 0.0 238.1 3.1 44.9 1.0 2.0 1.0 Investigated for use/treatment in colorectal cancer and lung cancer. KDR Tyr Cc1cc([nH]c1/C=C\2/c3ccccc3NC2=O)C WUWDLXZGHZSWQZ-WQLSENKSSA-N nan None Achiral Molecule NSC-696819
SEMAXANIB
SEMAXINIB
SU-5416
SU005416
SU5416
Dinaciclib
3 Schering-Plough ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 396.2 2.3 92.6 7.0 2.0 7.0 nan CDK4
CDK6
BRDT
CMGC
(*)
CCc1cnn2c1nc(cc2NCc3ccc[n+](c3)[O-])N4CCCC[C@H]4CCO PIMQWRZWLQKKBJ-SFHVURJKSA-N nan None Single Stereoisomer DINACICLIB
MK-7965
SCH 727965
SCH-727965
Dovitinib
3 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
ZINC
FDA SRS
BindingDB
'38O' 4tyi 5a46 5am6 5am7 5owq 7akg 1 0.0 392.2 2.5 94.0 5.0 3.0 2.0 nan FGFR3
VEGFA
FGFR1
PDGFRA
KIT
CSF1R
(*)
Tyr
CN1CCN(CC1)c2ccc3c(c2)[nH]c(n3)c4c(c5c(cccc5F)[nH]c4=O)N PIQCTGMSNWUMAF-UHFFFAOYSA-N nan None Achiral Molecule CHIR-258
DOVITINIB
GFKI-258
NVP-TKI258
TKI-258
Crenolanib
3 Arog Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'6T2' 5lby 6bqp 6joi 6joj 1 0.0 443.2 3.9 78.4 7.0 1.0 5.0 nan FLT3
PDGFRA
PDGFRB
Tyr CC1(COC1)COc2ccc3c(c2)ncn3c4ccc5cccc(c5n4)N6CCC(CC6)N DYNHJHQFHQTFTP-UHFFFAOYSA-N nan None Achiral Molecule ARO 002
ARO-002
CP 868596
CP-868,596
CP-868596
CRENOLANIB
Enzastaurin
Kinenza 3 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 515.2 4.9 72.2 6.0 1.0 5.0 nan nan Cn1cc(c2c1cccc2)C3=C(C(=O)NC3=O)c4cn(c5c4cccc5)C6CCN(CC6)Cc7ccccn7 AXRCEOKUDYDWLF-UHFFFAOYSA-N nan None Achiral Molecule DB-102
DB102
ENZASTAURIN
KINENZA
LY-317615
LY317615
Tolebrutinib
3 Principia Biopharma ChemSpider
PubChem
Guide to Pharmacology
FDA SRS
nan 0.0 455.2 3.9 95.4 7.0 1.0 5.0 nan nan C=CC(=O)N1CCCC(C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5 KOEUOFPEZFUWRF-LJQANCHMSA-N nan NaN NaN SAR442168
Ruboxistaurin
Arxxant 3 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'LY4' 1uu3 2j2i nan 0.0 468.2 3.5 68.5 6.0 1.0 2.0 nan nan CN(C)C[C@@H]1CCn2cc(c3c2cccc3)C4=C(c5cn(c6c5cccc6)CCO1)C(=O)NC4=O ZCBUQCWBWNUWSU-SFHVURJKSA-N nan None Single Stereoisomer ARXXANT
LY-333531
RUBOXISTAURIN
Rigosertib
3 Onconova Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'6FS' 5j18 5j2r 5ov7 3 0.0 451.1 2.8 120.4 8.0 2.0 11.0 nan PIK3CA
PLK1
Atypical
Other
COc1ccc(cc1NCC(=O)O)CS(=O)(=O)/C=C/c2c(cc(cc2OC)OC)OC OWBFCJROIKNMGD-BQYQJAHWSA-N nan None Achiral Molecule ON 01910
RIGOSERTIB
Cediranib
Recentin 3 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 450.2 5.2 72.5 6.0 1.0 8.0 For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors. KDR Tyr Cc1cc2c([nH]1)ccc(c2F)Oc3c4cc(c(cc4ncn3)OCCCN5CCCC5)OC XXJWYDDUDKYVKI-UHFFFAOYSA-N nan None Achiral Molecule AZD-2171
AZD2171
CEDIRANIB
RECENTIN
ZD-2171
Futibatinib
3 Taiho Pharmaceutical ChemSpider
ChEMBL
PubChem
BindingDB
nan 0.0 418.2 1.8 108.4 8.0 1.0 4.0 nan nan COc1cc(cc(c1)OC)C#Cc2c3c(ncnc3n(n2)C4CCN(C4)C(=O)C=C)N KEIPNCCJPRMIAX-UHFFFAOYSA-N nan None Single Stereoisomer
Itacitinib
3 Incyte Corporation ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 553.2 3.6 119.6 8.0 1.0 5.0 nan JAK1 Tyr c1cnc-2[nH]cnc(c12)c3cnn(c3)C4(CN(C4)C5CCN(CC5)C(=O)c6ccnc(c6F)C(F)(F)F)CC#N KTBSXLIQKWEBRB-UHFFFAOYSA-N nan None Achiral Molecule INCB-039110
INCB-39110
INCB039110
ITACITINIB
Ipatasertib
3 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'0RF' 4ekl 1 0.0 457.2 3.1 81.6 6.0 2.0 6.0 nan AKT1
AKT2
AKT3
AGC C[C@@H]1C[C@H](c2c1c(ncn2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)c4ccc(cc4)Cl)O GRZXWCHAXNAUHY-NSISKUIASA-N nan None Single Stereoisomer GDC-0068
IPATASERTIB
RG-7440
RG7440
Brivanib
3 Bristol Myers Squibb ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 370.1 3.5 84.7 6.0 2.0 5.0 nan KDR Tyr Cc1cc2c([nH]1)ccc(c2F)Oc3c4c(c(cn4ncn3)OC[C@@H](C)O)C WCWUXEGQKLTGDX-LLVKDONJSA-N nan None Single Stereoisomer BMS-540215
BRIVANIB
Vatalanib
3 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 346.1 5.0 50.7 4.0 1.0 4.0 Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC). FLT1
KDR
FLT4
Tyr c1ccc2c(c1)c(nnc2Nc3ccc(cc3)Cl)Cc4ccncc4 YCOYDOIWSSHVCK-UHFFFAOYSA-N nan None Achiral Molecule BAY-86-5127
CGP-79787
K-222584
NVP-PTK787
PTK-787
PTK787
VATALANIB
ZK-222584
Buparlisib
3 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'SD5' 3sd5 5m7e 1 0.0 410.2 1.8 89.6 8.0 1.0 3.0 nan PIK3CA Atypical c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F CWHUFRVAEUJCEF-UHFFFAOYSA-N nan None Achiral Molecule BKM-120
BKM-120NX
BKM120-NX
BUPARLISIB
NVP-BKM-120
NVP-BKM120
Brivanib alaninate
3 Bristol Myers Squibb ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 0.0 441.2 3.4 116.8 8.0 2.0 7.0 nan nan Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1 LTEJRLHKIYCEOX-OCCSQVGLSA-N nan None Single Stereoisomer BMS-582664
BMS-582664-02
BRIVANIB ALANINATE
BRIVANIB L-ALANINE ESTER
Lazertinib
3 Genosco ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
nan 1.0 554.3 4.1 109.7 10.0 2.0 10.0

Lazertinib (YH-25448, GNS-1480) is an inhibitor of the aberrant activity of EGFR mutant kinases, that was originally developed by Yuhan Corporation for antineoplastic potential in cancers with (acquired) resistance to existing EGFR tyrosine kinase inhibitors, in particular for EGFR mutation positive, advanced non-small cell lung cancer (NSCLC). In addition to predicted efficacy for the treatment of primary lung and extracranial lesions, lazertinib is expected to be beneficial for NSCLC brain metastases as it is able to cross the blood brain barrier.

nan CN(C)Cc1cn(nc1c2ccccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N5CCOCC5)NC(=O)C=C RRMJMHOQSALEJJ-UHFFFAOYSA-N nan None Achiral Molecule C-18112003-G
GNS-1480
GNS1480
JNJ-73841937-AAA
LAZERTINIB
YH-25448
YH25448
Fruquintinib
3 Hutchison MediPharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 0.0 393.1 3.9 95.7 7.0 1.0 5.0 nan FLT1
KDR
FLT4
Tyr Cc1c(c2ccc(cc2o1)Oc3c4cc(c(cc4ncn3)OC)OC)C(=O)NC BALLNEJQLSTPIO-UHFFFAOYSA-N nan None Single Stereoisomer FRUQUINTINIB
HMPL-013
HMPL013
Barasertib
3 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 587.2 3.6 174.8 9.0 5.0 15.0 nan AURKB Other CCN(CCCOc1ccc2c(c1)ncnc2Nc3cc(n[nH]3)CC(=O)Nc4cccc(c4)F)CCOP(=O)(O)O GBJVVSCPOBPEIT-UHFFFAOYSA-N nan None Achiral Molecule AZD 1152
AZD-1152
AZD1152
BARASERTIB
Abivertinib
3 ACEA Biosciences ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 487.2 4.5 98.4 7.0 3.0 7.0

AC0010 is an orally active, irreversible EGFR inhibitor that selectively targets mutated EGFRs, and was designed to overcome T790M-induced resistance in tumours [2]. It may also inhibit BTK, thus offering extended clinical utility [3]. We show the structure for the free base form of the compound.

nan CN1CCN(CC1)c2ccc(cc2F)Nc3nc4c(cc[nH]4)c(n3)Oc5cccc(c5)NC(=O)C=C UOFYSRZSLXWIQB-UHFFFAOYSA-N nan None Achiral Molecule A610
ABIVERTINIB
AC-0010
AC0010
ACEA100610
AVITINIB
EX-ACEA0010
Momelotinib
3 Ym Biosciences Australia ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'C87' 6fdz 7nns nan 0.0 414.2 3.0 103.2 7.0 2.0 6.0 nan JAK1
JAK2
JAK3
Tyr c1cc(ccc1c2ccnc(n2)Nc3ccc(cc3)N4CCOCC4)C(=O)NCC#N ZVHNDZWQTBEVRY-UHFFFAOYSA-N nan None Achiral Molecule CYT-0387
CYT-11387
CYT-387
CYT387
GS-0387
MOMELOTINIB
Motesanib
3 Amgen ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'706' 3efl 2 0.0 373.2 4.0 78.9 5.0 3.0 5.0 nan FLT1
KDR
FLT4
PDGFRA
PDGFRB
KIT
RET
Tyr CC1(CNc2c1ccc(c2)NC(=O)c3cccnc3NCc4ccncc4)C RAHBGWKEPAQNFF-UHFFFAOYSA-N nan None Achiral Molecule AMG 706
AMG-706
MOTESANIB
Filgotinib
3 Galapagos ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'2HB' 4p7e 5ut5 1 0.0 425.2 2.0 96.7 7.0 1.0 5.0 nan JAK1 Tyr c1cc(n2c(c1)nc(n2)NC(=O)C3CC3)c4ccc(cc4)CN5CCS(=O)(=O)CC5 RIJLVEAXPNLDTC-UHFFFAOYSA-N nan None Single Stereoisomer FILGOTINIB
G-146034
G146034
GLPG-0634
GLPG0634
GS-6034 FREE BASE
Lestaurtinib
3 Cephalon ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 439.2 3.5 88.7 6.0 3.0 1.0 nan FLT3 Tyr C[C@@]12[C@](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)(CO)O UIARLYUEJFELEN-LROUJFHJSA-N nan None Single Stereoisomer A-154475
A-154475.0
CEP-701
KT-555
KT-5555
KT5555
LESTAURTINIB
SP-924
SP924
SPM-924
Nazartinib
3 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 494.2 4.3 83.4 6.0 1.0 6.0 nan nan Cc1cc(ccn1)C(=O)Nc2nc3cccc(c3n2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)Cl IOMMMLWIABWRKL-WUTDNEBXSA-N nan None Single Stereoisomer EGF-816
EGF816
NAZARTINIB
NVP-EGF816-NX
Orantinib
3 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'SU6' 4jlc 5yvc 1 0.0 310.1 3.1 82.2 2.0 3.0 4.0 nan KDR
PDGFRB
FGFR1
Tyr Cc1c(c([nH]c1/C=C\2/c3ccccc3NC2=O)C)CCC(=O)O NHFDRBXTEDBWCZ-ZROIWOOFSA-N nan None Achiral Molecule NSC-702827
ORANTINIB
SU-6668
TSU-68
Capivasertib
3 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'0XZ' 4gv1 nan 0.0 428.2 2.1 120.2 6.0 4.0 6.0 nan AKT1 AGC c1cc(ccc1[C@H](CCO)NC(=O)C2(CCN(CC2)c3c4cc[nH]c4ncn3)N)Cl JDUBGYFRJFOXQC-KRWDZBQOSA-N nan None Single Stereoisomer AZC5363
AZD 5363
AZD-5363
AZD5363
CAPIVASERTIB
Naquotinib
3 Astellas Pharma ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'8RC' 5y9t nan 1.0 562.3 2.3 120.2 9.0 2.0 9.0 nan EGFR Tyr CCc1c(nc(c(n1)C(=O)N)Nc2ccc(cc2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C QKDCLUARMDUUKN-XMMPIXPASA-N nan None Single Stereoisomer ASP-8273
ASP8273
NAQUOTINIB
Linifanib
3 Abbott Laboratories ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 375.1 4.9 95.8 3.0 4.0 3.0 nan FLT3
CSF1R
KDR
Tyr Cc1ccc(c(c1)NC(=O)Nc2ccc(cc2)c3cccc4c3c(n[nH]4)N)F MPVGZUGXCQEXTM-UHFFFAOYSA-N nan None Achiral Molecule A-741439
ABT-869
AL-39324
LINIFANIB
RG-3635
Dactolisib
3 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 469.2 5.9 76.5 6.0 0.0 3.0 nan PIK3CA
PIK3CB
PIK3CG
PIK3CD
MTOR
Atypical CC(C)(C#N)c1ccc(cc1)n2c3c4cc(ccc4ncc3n(c2=O)C)c5cc6ccccc6nc5 JOGKUKXHTYWRGZ-UHFFFAOYSA-N nan None Achiral Molecule BEZ-235
BEZ235
DACTOLISIB
NVP-BEZ235
NVP-BEZ235-NX
RTB-101
RTB101
Aumolertinib
3 Jiangsu Hansoh Pharmaceutical ChemSpider
PubChem
Guide to Pharmacology
FDA SRS
nan 2.0 525.3 5.3 87.6 8.0 2.0 11.0 nan nan CN(C)CCN(C)C1C=C(OC)C(=CC=1NC(=O)C=C)NC1N=C(C=CN=1)C1=CN(C2CC2)C2C=CC=CC=21 DOEOECWDNSEFDN-UHFFFAOYSA-N nan None Unknown
Almonertinib
HS-10296
EQ143
AMEILE
Asciminib
3 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
'AY7' 5mo4 nan 0.0 449.1 3.5 103.4 6.0 3.0 6.0 nan nan c1cc(ccc1NC(=O)c2cc(c(nc2)N3CC[C@H](C3)O)c4ccn[nH]4)OC(F)(F)Cl VOVZXURTCKPRDQ-CQSZACIVSA-N nan None Single Stereoisomer ABL-001
ABL001
ABL001-NX
ASCIMINIB
NVP-ABL001
Losmapimod
3 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 383.2 3.9 71.1 3.0 2.0 5.0 nan MAPK14
MAPK11
MAPK13
MAPK12
CMGC Cc1c(cc(cc1F)C(=O)NC2CC2)c3ccc(cn3)C(=O)NCC(C)(C)C KKYABQBFGDZVNQ-UHFFFAOYSA-N nan None Achiral Molecule FTX-1821
FTX1821
GSK-AHAB
GSKAHAB
GW-856553
GW-856553X
GW856553X
LOSMAPIMOD
Alvocidib
3 Sanofi ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'CPB' 1c8k 1e1y 3blr 3ebp 4o71 nan 0.0 401.1 3.3 94.1 6.0 3.0 2.0 Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified). nan CN1CC[C@@H]([C@@H](C1)O)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O BIIVYFLTOXDAOV-YVEFUNNKSA-N nan None Single Stereoisomer ALVOCIDIB
FLAVOPIRIDOL
HL 275
HL-275
HMR 1275
HMR-1275
L 86 8275
L-868275
L86-8275
MDL 107,826A
MDL-107826A
NSC-649890
Alisertib
3 Millennium Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'A5B' 5ia0 1 2.0 518.1 5.7 105.9 7.0 2.0 6.0 For the treatment of various forms of cancer. AURKA Other COc1cccc(c1C2=NCc3cnc(nc3-c4c2cc(cc4)Cl)Nc5ccc(c(c5)OC)C(=O)O)F ZLHFILGSQDJULK-UHFFFAOYSA-N nan None Achiral Molecule ALISERTIB
MLN 8237
MLN-8237
MLN8237
Volasertib
3 Boehringer Ingelheim ChemSpider
ChEMBL
DrugBank
RCSB
PDBe
Guide to Pharmacology
FDA SRS
BindingDB
'IBI' 3fc2 5v67 5vbr 7lak 7lej 7n7n 1 1.0 618.4 4.3 106.2 9.0 2.0 10.0 nan PLK1 Other CC[C@H]1N(c2nc(ncc2N(C1=O)C)Nc3c(cc(cc3)C(=O)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6)OC)C(C)C SXNJFOWDRLKDSF-STROYTFGSA-N nan None Single Stereoisomer BI 6727
BI-6727
VOLASERTIB
Alflutinib
3 Allist Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
nan 1.0 568.3 4.8 100.4 9.0 2.0 11.0 nan nan C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OCC(F)(F)F)nc1N(C)CCN(C)C GHKOONMJXNWOIW-UHFFFAOYSA-N nan None Achiral Molecule ALFLUTINIB
AST-2818
AST2818
FURMONERTINIB
Linsitinib
3 Osi Pharmaceuticals ChemSpider
ChEMBL
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 421.2 4.8 89.3 6.0 2.0 3.0 nan IGF1R Tyr C[C@]1(C[C@@H](C1)c2n3c(c(ncc3)N)c(n2)c4cc5nc(ccc5cc4)c6ccccc6)O PKCDDUHJAFVJJB-VLZXCDOPSA-N nan None Single Stereoisomer ASP-7487
LINSITINIB
OSI-906
OSI-906AA
Ponatinib
Iclusig 4 Ariad Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'0LI' 3ik3 3oxz 3zos 4c8b 4qrc 4tyj 4u0i 4uxq 4v01 4v04 6eg9 6p3d 6tu9 2 1.0 532.2 4.5 65.8 6.0 1.0 4.0

Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.

ABL1
BCR
KIT
RET
TEK
FLT3
FGFR1
FGFR2
FGFR3
FGFR4
LCK
SRC
LYN
KDR
PDGFRA
Atypical
Tyr
Cc1ccc(cc1C#Cc2cnc3n2nccc3)C(=O)Nc4ccc(c(c4)C(F)(F)F)CN5CCN(CC5)C PHXJVRSECIGDHY-UHFFFAOYSA-N 2012 US-8114874-B2 Achiral Molecule AP-24534
AP24534
ICLUSIG
PONATINIB
Y
Ribociclib
Kisqali 4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'6ZZ' 5l2t 1 0.0 434.3 2.8 91.2 8.0 2.0 5.0

Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.

CDK4
CDK6
CMGC CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5 RHXHGRAEPCAFML-UHFFFAOYSA-N 2017 US-8324225-B2 Achiral Molecule LEE-011
LEE-011A
LEE011
LEE011A
NVP-LEE011
RIBOCICLIB
Y
Ripretinib
Qinlock 4 Deciphera Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
nan 2.0 509.1 5.7 88.0 5.0 3.0 5.0

Ripretinib (DCC-2618) is an orally bioavailable, potent pan-KIT and PDGFRα kinase inhibitor being developed by Dicephera Pharmaceuticals. It is in clinical development for the treatment of malignancies that are driven by KIT and/or PDGFRα, for example gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Ripretinib has activity across a broad range of resistance mutations in its target kinases, that emerge in response to imatinib treatment. Ripretinib binds to the 'switch pocket' of KIT, a domain that regulates the enzyme's catalytic conformation. Compounds that act in this way are often referred to as switch control inhibitors.

nan CCn1c2cc(ncc2cc(c1=O)c3cc(c(cc3Br)F)NC(=O)Nc4ccccc4)NC CEFJVGZHQAGLHS-UHFFFAOYSA-N 2020 US-8188113-B2 Achiral Molecule DCC-2618
QINLOCK
RIPRETINIB
Y
Ruxolitinib
Jakafi;Jakavi 4 Incyte Corporation ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'RXT' 4u5j 6vgl 6vnk 6wtn 1 0.0 306.2 3.5 83.2 5.0 1.0 4.0

Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).

JAK1
JAK2
Tyr c1c[nH]c2c1c(ncn2)c3cnn(c3)[C@H](CC#N)C4CCCC4 HFNKQEVNSGCOJV-OAHLLOKOSA-N 2011 US-7598257-B2 Single Stereoisomer INC-424
INC424
INCB-018424
INCB-18424
INCB018424
JAKAVI
RUXOLITINIB
Y
Selpercatinib
Retevmo 4 Loxo Oncology ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB
nan 1.0 525.2 3.3 112.0 10.0 1.0 8.0 On May 2020 FDA approved selpercatinib to treat lung and thyroid cancers. nan COC1C=CC(CN2C3CN(CC2C3)C2C=CC(=CN=2)C2=CC(=CN3N=CC(C#N)=C32)OCC(C)(C)O)=CN=1 XIIOFHFUYBLOLW-UHFFFAOYSA-N 2020 US-10112942-B2 Achiral Molecule LOXO-292
LY-3527723
LY3527723
RETEVMO
SELPERCATINIB
Y
Selumetinib
4 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'3EW' 4u7z 7jut 7juz 7m0t 3 0.0 456.0 3.5 88.4 6.0 3.0 6.0 On April 2020 FDA approved selumetinib to treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves. MAP2K1
MAP2K2
STE Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3Cl)Br)C(=O)NOCCO CYOHGALHFOKKQC-UHFFFAOYSA-N 2020 US-7425637-B2 Achiral Molecule ARRY-142886
ARRY-886
AZD-6244
AZD6244
SELUMETINIB
Y
Sorafenib
Nexavar 4 Bayer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'BAX' 1uwh 1uwj 3gcs 3heg 3rgf 3wze 4asd 5hi2 2 1.0 464.1 5.5 92.3 4.0 3.0 5.0 Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. BRAF
RAF1
FLT4
KDR
FLT3
PDGFRB
KIT
FGFR1
RET
FLT1
TKL
Tyr
CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl MLDQJTXFUGDVEO-UHFFFAOYSA-N 2005 US-7235576-B1 Achiral Molecule BAY 43-9006
BAY-43-9006
NEXAVAR
SORAFENIB
Y 205.6 °C
Tivozanib
Fotivda 4 Aveo Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'AV9' 4ase 2 1.0 454.1 5.6 107.7 7.0 2.0 6.0 On March 2021, FDA approved tivozanib to treat patients with renal cell carcinoma FLT1
KDR
FLT4
Tyr Cc1cc(no1)NC(=O)Nc2ccc(cc2Cl)Oc3ccnc4c3cc(c(c4)OC)OC SPMVMDHWKHCIDT-UHFFFAOYSA-N 2021 None Achiral Molecule ASP-4130
AV-951
FOTIVDA
KIL-8951
KIL8951
KRN-951
TIVOZANIB
Y
Tofacitinib
Xeljanz 4 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'MI1' 3eyg 3fup 3lxk 3lxn 4oti 1 0.0 312.2 1.5 88.9 5.0 1.0 3.0

For the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.

JAK1
JAK2
JAK3
TYK2
Tyr C[C@@H]1CCN(C[C@@H]1N(C)c2c3cc[nH]c3ncn2)C(=O)CC#N UJLAWZDWDVHWOW-YPMHNXCESA-N 2012 US-6956041-B2 Single Stereoisomer 550
CP 690550
CP- 690 550
CP-690
CP-690,550
CP-690,550 FREE BASE
CP-690-550
CP-690550
CP-690550 FREE BASE
CP690,550
CP690550
TASOCITINIB
TOFACITINIB
Y White crystalline solid. MP: 199-206 °C /Tofacitinib monocitrate/
Trametinib
Mekinist 4 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'QOM' 7jur 7jux 7m0y 3 1.0 615.1 3.9 107.1 8.0 2.0 5.0

Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.

BRAF
MAP2K1
MAP2K2
TKL
STE
Cc1c2c(c(n(c1=O)C)Nc3ccc(cc3F)I)c(=O)n(c(=O)n2c4cccc(c4)NC(=O)C)C5CC5 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 2013 US-7378423-B2 Achiral Molecule GSK-1120212
GSK1120212
JTP 74057
JTP-74057
MEKINIST
TMT-212
TMT212
TRAMETINIB
Y 293-303
Tucatinib
Tukysa 4 Array BioPharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 1.0 480.2 5.1 110.9 10.0 2.0 5.0 On April 2020, FDA approved tucatinib to treat advanced unresectable or metastatic HER2-positive breast cancer. ERBB2 Tyr Cc1cc(ccc1Oc2ccn3c(c2)ncn3)Nc4c5cc(ccc5ncn4)NC6=NC(CO6)(C)C SDEAXTCZPQIFQM-UHFFFAOYSA-N 2020 US-7452895-B2 Achiral Molecule ARRY-380
ONT-380
TUCATINIB
TUKYSA
Y 230
Vandetanib
Caprelsa;Zactima 4 Ipr Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'ZD6' 2ivu 1.5 1.0 474.1 5.0 59.5 6.0 1.0 6.0

Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

VEGFA
EGFR
PTK6
TEK
RET
(*)
Tyr
CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br UHTHHESEBZOYNR-UHFFFAOYSA-N 2011 US-7173038-B1 Achiral Molecule CAPRELSA
GNF-PF-2188
VANDETANIB
ZACTIMA
ZD-64
ZD-6474
ZD6474
Y
Upadacitinib
Rinvoq 4 Abbvie ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 0.0 380.2 2.9 78.3 4.0 2.0 3.0 On august 2019, FDA approved fedratinib to treat adults with moderately to severely active rheumatoid arthritis JAK1 Tyr CC[C@@H]1CN(C[C@@H]1c2cnc3n2c4cc[nH]c4nc3)C(=O)NCC(F)(F)F WYQFJHHDOKWSHR-MNOVXSKESA-N 2019 US-8962629-B2 Single Stereoisomer ABT-494
RINVOQ
UPADACITINIB
Y 16-19
Icotinib
4 Zhejiang Beta Pharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 391.2 3.2 74.7 7.0 1.0 2.0

Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.

EGFR Tyr C#Cc1cccc(c1)Nc2c3cc4c(cc3ncn2)OCCOCCOCCO4 QQLKULDARVNMAL-UHFFFAOYSA-N 2011 None Achiral Molecule BPI-2009H
ICOTINIB
N
Sunitinib
Sutent 4 Cp Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'B49' 2y7j 3g0e 3g0f 3miy 3ti1 4agd 4ks8 4qmz 6jok 6m11 6nfy 6nfz 6ng0 6v0x 1 0.0 398.2 3.3 77.2 3.0 3.0 7.0

For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.

PDGFRB
FLT1
KIT
KDR
FLT4
FLT3
CSF1R
PDGFRA
Tyr CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C WINHZLLDWRZWRT-ATVHPVEESA-N 2006 US-6573293-B2 Achiral Molecule SU-011248
SU-11248
SU011248
SUNITINIB
SUTENT
Y
Pexidartinib
Turalio 4 Daiichi Sankyo ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'P31' 4r7h 7khg 2 1.0 417.1 5.2 66.5 4.0 2.0 5.0 On august 2019, FDA approved pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor FLT3
KIT
CSF1R
Tyr c1cc(ncc1Cc2c[nH]c3c2cc(cn3)Cl)NCc4ccc(nc4)C(F)(F)F JGWRKYUXBBNENE-UHFFFAOYSA-N 2019 US-7893075-B2 Achiral Molecule CML-261
PEXIDARTINIB
PLX-3397
PLX3397
Y
Palbociclib
Ibrance 4 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'LQQ' 2euf 5l2i 7n7o 1 0.0 447.2 3.0 105.0 9.0 2.0 5.0

Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

CDK4
CDK6
CMGC Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5 AHJRHEGDXFFMBM-UHFFFAOYSA-N 2015 US-6936612-B2 Achiral Molecule IBRANCE
PALBOCICLIB
PD-0332991
Y 263-266 ºC
Idelalisib
Zydelig 4 Gilead Sciences ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'40L' 4xe0 1 0.0 415.2 3.8 101.4 7.0 2.0 5.0

Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.

PIK3CD Atypical CC[C@@H](c1nc2cccc(c2c(=O)n1c3ccccc3)F)Nc4c5c([nH]cn5)ncn4 IFSDAJWBUCMOAH-HNNXBMFYSA-N 2014 US-6800620-B2 Single Stereoisomer CAL-101
GS-1101
GS-11CAL-101
IDELALISIB
ZYDELIG
Y
Regorafenib
Stivarga 4 Bayer ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
2 1.0 482.1 5.7 92.3 4.0 3.0 5.0

Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

FLT1
KDR
FLT4
KIT
PDGFRA
PDGFRB
FGFR1
FGFR2
TEK
DDR2
NTRK1
EPHA2
RAF1
BRAF
MAPK11
FRK
ABL1
RET
CMGC
TKL
Tyr
CNC(=O)c1cc(ccn1)Oc2ccc(c(c2)F)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl FNHKPVJBJVTLMP-UHFFFAOYSA-N 2012 US-7351834-B1 Achiral Molecule BAY 73-4506
BAY 73-4506 MONOHYDRATE
BAY-73-4506
BAY-734506
REGORAFENIB
STIVARGA
Y
Neratinib
Nerlynx 4 Puma Biotechnology ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 2.0 556.2 5.9 112.4 8.0 2.0 11.0

For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy

ERBB2
EGFR
Tyr CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)OCc4ccccn4 JWNPDZNEKVCWMY-VQHVLOKHSA-N 2017 US-7399865-B2 Achiral Molecule CDP-820
HKI-272
NERATINIB
WAY-179272
Y
Pazopanib
Votrient 4 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
1 0.0 437.2 3.1 119.0 8.0 2.0 5.0 Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) FLT1
KDR
FLT4
PDGFRA
PDGFRB
KIT
FGFR3
ITK
FGFR1
Tyr Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C CUIHSIWYWATEQL-UHFFFAOYSA-N 2009 US-7105530-B2 Achiral Molecule GW786034
PAZOPANIB
VOTRIENT
Y
Ibrutinib
Imbruvica 4 Pharmacyclics ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'1E8' 4ifg 4rz7 5p9i 5yu9 6l8l 6yg2 6yz4 1.5 0.0 440.2 4.2 99.2 7.0 1.0 5.0

Ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia

BTK Tyr C=CC(=O)N1CCC[C@H](C1)n2c3c(c(n2)c4ccc(cc4)Oc5ccccc5)c(ncn3)N XYFPWWZEPKGCCK-GOSISDBHSA-N 2013 US-7514444-B2 Single Stereoisomer CRA-032765
IBRUTINIB
IMBRUVICA
PC-32765
PCI 32765
PCI-32765
PCI-32765-00
Y 149-158ºC
Osimertinib
Tagrisso 4 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'YY3' 4zau 6jwl 6jx0 6jx4 6jxt 6lud 1 0.0 499.3 4.5 87.6 8.0 2.0 10.0

Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.

EGFR Tyr Cn1cc(c2c1cccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N(C)CCN(C)C)NC(=O)C=C DUYJMQONPNNFPI-UHFFFAOYSA-N 2015 US-8946235-B2 Achiral Molecule AZD-9291
AZD-9291 FREE BASE
AZD9291
OSIMERTINIB
TAGRISSO
MERELETINIB
Y
Nintedanib
Ofev;Vargatef 4 Boehringer Ingelheim ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'XIN' 3c7q 5maf 5te0 6nec 1 1.0 539.3 3.6 94.2 7.0 2.0 7.0 Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). FLT1
KDR
FLT4
FGFR1
FGFR2
FGFR3
FLT3
LCK
LYN
SRC
Tyr CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4NC3=O)C(=O)OC)/c5ccccc5 XZXHXSATPCNXJR-ZIADKAODSA-N 2014 US-6762180-B1 Achiral Molecule BIBF 1120
BIBF-1120
BIBF1120
INTEDANIB
NINTEDANIB
OFEV
VARGATEF
Y
Nilotinib
Tasigna 4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'NIL' 3cs9 3gp0 5mo4 2 2.0 529.2 6.4 97.6 7.0 2.0 6.0 For the potential treatment of various leukemias, including chronic myeloid leukemia (CML). ABL1
KIT
Tyr Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F HHZIURLSWUIHRB-UHFFFAOYSA-N 2007 US-7169791-B2 Achiral Molecule AMN 107
AMN-107
AMN107
NILOTINIB
TASIGNA
Y
Netarsudil
Rhopressa 4 Aerie Pharmaceutical ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 0.0 453.2 4.9 94.3 5.0 2.0 7.0 On december 18, 2017, the FDA approved netarsudil to treat glaucoma or ocular hypertension nan Cc1ccc(c(c1)C)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3 OURRXQUGYQRVML-AREMUKBSSA-N 2017 US-8394826-B2 Single Stereoisomer AR-11324 FREE BASE
AR-13324
NETARSUDIL
Y
Midostaurin
Rydapt 4 Novartis Pharmaceuticals Corp ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'2K2' 4nct nan 2.0 570.2 5.9 77.7 6.0 1.0 3.0 On april 28 , 2017, the FDA approved midostaurin to treat acute myeloid leukemia nan C[C@@]12[C@@H]([C@@H](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)N(C)C(=O)c9ccccc9)OC BMGQWWVMWDBQGC-IIFHNQTCSA-N 2017 US-7973031-B2 Single Stereoisomer CGP 41251
CGP-41251
MIDOSTAURIN
NVP-PKC412
PKC 412
PKC-412
RYDAPT
Y 235-260
Zanubrutinib
Brukinsa 4 BeiGene ChemSpider
ChEMBL
PubChem
BindingDB
nan 0.0 471.2 4.2 102.5 6.0 2.0 6.0

Zanubrutinib (BGB-3111) is a potent, selective and and irreversible BTK inhibitor that is being investigated for clinical utility in the treatment of hematological cancers, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL) [1-2].

nan C=CC(=O)N1CCC(CC1)C2CCNc3n2nc(c3C(=O)N)c4ccc(cc4)Oc5ccccc5 RNOAOAWBMHREKO-UHFFFAOYSA-N 2019 US-9447106-B2 Single Stereoisomer Y
Lorlatinib
Lorbrena 4 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'5P8' 4cli 4clj 4uxl 5a9u 5aa8 5aa9 1 0.0 406.2 2.8 110.1 7.0 1.0 0.0

On november 2, 2018, the FDA approved lorlatinib to treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

ALK
ROS1
Tyr C[C@@H]1c2cc(ccc2C(=O)N(Cc3c(c(n(n3)C)C#N)-c4cc(c(nc4)N)O1)C)F IIXWYSCJSQVBQM-LLVKDONJSA-N 2018 US-8680111-B2 Single Stereoisomer LORBRENA
LORLATINIB
PF-06463922
Y
Lenvatinib
Kisplyx;Lenvima 4 Eisai ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'LEV' 3wzd 5zv2 1.5 0.0 426.1 4.1 115.6 5.0 3.0 6.0

Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.

FLT1
KDR
FLT4
FGFR1
FGFR2
FGFR3
FGFR4
KIT
Tyr COc1cc2c(cc1C(=O)N)c(ccn2)Oc3ccc(c(c3)Cl)NC(=O)NC4CC4 WOSKHXYHFSIKNG-UHFFFAOYSA-N 2015 US-7253286-B2 Achiral Molecule E-7080
ER-203492-00
KISPLYX
LENVATINIB
LENVIMA
Y
Larotrectinib
Vitrakvi 4 Array BioPharma ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 428.2 2.9 86.0 6.0 2.0 3.0 On november 26, 2018, the FDA approved larotrectinib to treat patients whose cancers have a specific genetic feature (biomarker) NTRK1
NTRK2
NTRK3
Tyr c1cc(c(cc1F)[C@H]2CCCN2c3ccn4c(n3)c(cn4)NC(=O)N5CC[C@@H](C5)O)F NYNZQNWKBKUAII-KBXCAEBGSA-N 2018 US-8513263-B2 Single Stereoisomer ARRY-470
BAY-2757556
BAY2757556
LAROTRECTINIB
LOXO-101
Y
Lapatinib
Tykerb;Tyverb 4 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'FMM' 1xkk 3bbt 1.5 2.0 580.1 6.1 106.4 8.0 2.0 11.0

Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.

EGFR
ERBB2
Tyr CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F BCFGMOOMADDAQU-UHFFFAOYSA-N 2007 US-6713485-B2 Achiral Molecule GSK-572016
GW-2016
GW-572016
GW-572016X
GW572016
LAPATINIB
TYVERB
Y
Imatinib
Gleevec 4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'STI' 1iep 1opj 1t46 1xbb 2hyy 2oiq 2pl0 3fw1 3gvu 3hec 3k5v 3ms9 3mss 3oez 3pyy 4bkj 4csv 4r7i 5mqt 6hd4 6hd6 6jol 6ktn 6npe 6npu 6npv 6vxh 2 0.0 493.3 4.6 86.3 7.0 2.0 7.0

For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).

KIT
RET
NTRK1
CSF1R
PDGFRA
DDR1
ABL1
PDGFRB
Tyr Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C KTUFNOKKBVMGRW-UHFFFAOYSA-N 2001 US-6958335-B2 Achiral Molecule GLEEVEC
IMATINIB
STI-571
Y 226°C (mesylate salt)
Pemigatinib
Pemazyre 4 Incyte Corporation ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB
nan 0.0 487.2 3.7 83.2 6.0 1.0 6.0 On April 2020, FDA approved pemigatinib to treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts. nan CCN1c2c3cc([nH]c3ncc2CN(C1=O)c4c(c(cc(c4F)OC)OC)F)CN5CCOCC5 HCDMJFOHIXMBOV-UHFFFAOYSA-N 2020 US-9611267-B2 Achiral Molecule INCB054828
PEMAZYRE
PEMIGATINIB
Y
Gilteritinib
Xospata 4 Astellas Pharma ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'C6F' 6jqr 7ab1 nan 1.0 552.4 2.7 121.1 10.0 3.0 9.0 On november 28, 2018, the FDA approved gilteritinib to treat patients who have relapsed or refractory acute myeloid leukemia (AML) FLT3
AXL
ALK
Tyr CCc1c(nc(c(n1)C(=O)N)Nc2ccc(c(c2)OC)N3CCC(CC3)N4CCN(CC4)C)NC5CCOCC5 GYQYAJJFPNQOOW-UHFFFAOYSA-N 2018 US-8969336-B2 Achiral Molecule ASP-2215
ASP2215
GILTERITINIB
Y
Cabozantinib
Cabometyx;Cometriq 4 Exelixis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
2 2.0 501.2 5.5 98.8 6.0 2.0 8.0

For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

MET
KDR
RET
Tyr COc1cc2c(ccnc2cc1OC)Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F ONIQOQHATWINJY-UHFFFAOYSA-N 2012 US-7579473-B2 Achiral Molecule BMS-907351
BMS-907351 FREE BASE
CABOMETYX
CABOZANTINIB
COMETRIQ
XL-184
XL-184 FREE BASE
XL184
Y
Acalabrutinib
Calquence 4 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 465.2 3.3 118.5 7.0 2.0 4.0 Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy BTK Tyr CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5 WDENQIQQYWYTPO-IBGZPJMESA-N 2017 US-7459554-B2 Single Stereoisomer ACALABRUTINIB
ACP-196
CALQUENCE
Y
Duvelisib
Copiktra 4 Infinity Pharmacueticals ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 416.1 4.5 88.5 6.0 2.0 4.0

On october 27, 2018, the FDA approved duvelisib to treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma

PIK3CD
PIK3CG
Atypical C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)Cl)Nc4c5c([nH]cn5)ncn4 SJVQHLPISAIATJ-ZDUSSCGKSA-N 2018 US-8193182-B2 Single Stereoisomer COPIKTRA
DUVELISIB
INK-1147
INK-1197
IPI-145
Y >190 ºC
Encorafenib
Braftovi 4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 1.0 539.2 3.9 140.1 9.0 3.0 9.0

On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

BRAF TKL C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC CMJCXYNUCSMDBY-ZDUSSCGKSA-N 2018 US-8501758-B2 Single Stereoisomer BRAFTOVI
ENCORAFENIB
LGX-818
NVP-LGX-818-NXA
NVP-LGX818
NVP-LGX818-NXA
Y
Entrectinib
Rozlytrek 4 Ignyta ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'YMX' 5fto 5kvt 1 2.0 560.3 5.0 85.5 6.0 3.0 7.0

On august 2019, FDA approved entrectinib to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and to treat adult and pediatric patients 12 years of age and older with solid tumors

NTRK1
NTRK2
NTRK3
ROS1
ALK
Tyr CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4c5cc(ccc5[nH]n4)Cc6cc(cc(c6)F)F HAYYBYPASCDWEQ-UHFFFAOYSA-N 2019 US-8299057-B2 Achiral Molecule ENTRECTINIB
NMS-E628
ROZLYTREK
RXDX-101
Y
Erdafitinib
Balversa 4 Janssen ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'5SF' 5ew8 1 0.0 446.2 4.2 77.3 8.0 1.0 9.0 On april 2019, FDA approved erdafitinib to treat adult patients with locally advanced or metastatic bladder cancer FGFR1 Tyr CC(C)NCCN(c1ccc2c(c1)nc(cn2)c3cnn(c3)C)c4cc(cc(c4)OC)OC OLAHOMJCDNXHFI-UHFFFAOYSA-N 2019 US-8895601-B2 Achiral Molecule BALVERSA
ERDAFITINIB
JNJ-42756493
Y
Erlotinib
Tarceva 4 Osi Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'AQ4' 1m17 4hjo 6dwn 1.5 0.0 393.2 3.4 74.7 7.0 1.0 10.0

For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

EGFR
NR1I2
(*)
Tyr
COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C AAKJLRGGTJKAMG-UHFFFAOYSA-N 2004 US-6900221-B1 Achiral Molecule CP-358,774
CP-358774
CP-35877401
ERLOTINIB
OSI-774
R-1415
RG-1415
RO-508231
TARCEVA
Y
Fasudil
4 Asahi Kasei Pharma Corp ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'M77' 1q8w 2esm 2f2u 2gni 3tku 5lcp 5nw8 5o0e 5ok3 5vef 6em2 6emb 6ers 6erw 6i2a 6i2c 6yna nan 0.0 291.1 1.2 62.3 4.0 1.0 2.0 Fasudil is a potent inhibitor of the Rho-kinases ROCK1 and ROCK2. nan c1cc2cnccc2c(c1)S(=O)(=O)N3CCCNCC3 NGOGFTYYXHNFQH-UHFFFAOYSA-N nan None Achiral Molecule AT 877
AT-877
FASUDIL
HA 1077
HA-1077
ZK-258594
N
Fedratinib
Inrebic 4 Sanofi ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'2TA' 4ogj 4ps5 6vne nan 1.0 524.3 4.8 108.5 8.0 3.0 10.0 On august 2019, FDA approved fedratinib to treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis JAK2
FLT3
BRD4
(*)
Tyr
Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)OCCN4CCCC4 JOOXLOJCABQBSG-UHFFFAOYSA-N 2019 US-7528143-B2 Achiral Molecule FEDRATINIB
SAR-302503
SAR302503
TG-101348
TG101348
Y
Flumatinib
4 Jiangsu Hengrui Medicine ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 2.0 562.2 5.0 99.2 8.0 2.0 7.0 nan BCR
ABL1
PDGFRB
KIT
Atypical
Tyr
Cc1c(cc(cn1)NC(=O)c2ccc(c(c2)C(F)(F)F)CN3CCN(CC3)C)Nc4nccc(n4)c5cccnc5 BJCJYEYYYGBROF-UHFFFAOYSA-N nan None Achiral Molecule FLUMATINIB
HH-GV678
HHGV-678
N
Fostamatinib
Tavalisse 4 Rigel Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'2RC' 4o75 nan 2.0 580.1 3.1 186.7 12.0 4.0 10.0 Indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment SYK Tyr CC1(C(=O)N(c2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)COP(=O)(O)O)C GKDRMWXFWHEQQT-UHFFFAOYSA-N 2018 US-7449458-B2 Achiral Molecule FOSTAMATINIB
R-788
R-788 FREE ACID
R-935788
R-935788 FREE ACID
R788 FREE ACID
R935788 FREE ACID
Y
Vemurafenib
Zelboraf 4 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'032' 3og7 4rzv 5hes 1.5 1.0 489.1 5.5 91.9 4.0 2.0 7.0

Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.

BRAF TKL CCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c2c[nH]c3c2cc(cn3)c4ccc(cc4)Cl)F GPXBXXGIAQBQNI-UHFFFAOYSA-N 2011 US-7504509-B2 Achiral Molecule PLX-4032
PLX4032
RG 7204
RG-7204
RO 5185426
RO-51-85426
RO-5185426
VEMURAFENIB
ZELBORAF
Y 272°C
Abemaciclib
Verzenio;Verzenios 4 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'6ZV' 5l2s 1 1.0 506.3 4.9 75.0 8.0 1.0 7.0

On September 28, 2017, the Food and Drug Administration approved abemaciclib (VERZENIO, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In addition, abemaciclib was approved as monotherapy for women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

CDK4
CDK6
CMGC CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(c(n3)c4cc5c(c(c4)F)nc(n5C(C)C)C)F UZWDCWONPYILKI-UHFFFAOYSA-N 2017 US-7855211-B2 Achiral Molecule ABEMACICLIB
LY-2835219
LY2835219
VERZENIO
VERZENIOS
Y
Umbralisib
4 TG Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 2.0 571.2 6.7 109.1 8.0 1.0 6.0 On February 2021, FDA approved umbralisib for the treatment of certain patients with marginal zone lymphoma and follicular lymphoma nan C[C@@H](c1c(c(=O)c2cc(ccc2o1)F)c3cccc(c3)F)n4c5c(c(n4)c6ccc(c(c6)F)OC(C)C)c(ncn5)N IUVCFHHAEHNCFT-INIZCTEOSA-N 2021 None Single Stereoisomer RP-5264
RP5264
TGR 1202
TGR-1202 BASE
TGR-1202 FREE BASE
UMBRALISIB
Y
Pralsetinib
Gavreto 4 Blueprint Medicines ChemSpider
ChEMBL
DrugBank
RCSB
PDBe
FDA SRS
'Q4J' 7ju5 nan 1.0 533.3 4.2 135.5 9.0 3.0 8.0

Pralsetinib, also known as BLU-667, is a highly potent, selective, next generation RET inhibitor. BLU-667 is a potent and selective inhibitor of RET mutations, fusions, and predicted resistant mutants. RET fusions are key drivers of multiple cancers, including lung and thyroid cancer, and our research suggests that RET also plays a key role in some colon and breast cancers. By simultaneously targeting the primary driver and predicted resistant mutants that render cancer cells insensitive to treatment with currently approved drugs

nan Cc1[nH]nc(c1)Nc2nc(nc(c2)C)[C@H]3CC[C@@](CC3)(OC)C(=O)N[C@H](c4cnc(cc4)n5ncc(c5)F)C GBLBJPZSROAGMF-BATDWUPUSA-N 2020 None Single Stereoisomer GAVRETO (US
BLU123244
X-581238
BLU-123244
X581238
BLU-667
Y
Trilaciclib
4 G1 Therapeutics ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 446.3 2.7 91.2 8.0 2.0 3.0 On February 2021, FDA approved trilaciclib to mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer CDK4
CDK6
CMGC CN1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O PDGKHKMBHVFCMG-UHFFFAOYSA-N 2021 None Achiral Molecule G1T28
TRILACICLIB
Y
Infigratinib
4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'07J' 3tt0 1 2.0 559.2 5.4 95.1 8.0 2.0 8.0 On May 2021, FDA approved infigratinib to treat adults with cholangiocarcinoma whose disease meets certain criteria FGFR1
FGFR2
FGFR3
Tyr CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl QADPYRIHXKWUSV-UHFFFAOYSA-N 2021 None Achiral Molecule BGJ-398
BGJ398
INFIGRATINIB
MVP-BGJ398
NVP-BGJ398
Y
Dasatinib
Dasatinib;Sprycel 4 Bristol Myers Squibb ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'1N1' 2gqg 2y6o 2zva 3g5d 3k54 3lfa 3oct 3oht 3qlg 3sxr 4qms 4xey 4xli 5bvw 5h2u 5i9y 5owr 5vcv 6bsd 6fnm 1 0.0 487.2 3.3 106.5 9.0 3.0 7.0

For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.

ABL1
SRC
EPHA2
LCK
YES1
KIT
PDGFRB
ABL2
FYN
Tyr Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 2006 US-6596746-B1 Achiral Molecule BMS-354825
BMS-354825 HYDRATE
BMS-354825-03
DASATINIB
DASATINIB HYDRATE
DASATINIB MONOHYDRATE
SPRYCEL
Y 280-286 °C
Ceritinib
Zykadia 4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'4MK' 4mkc 1 2.0 557.2 6.4 105.2 8.0 3.0 9.0

Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

ALK Tyr Cc1cc(c(cc1C2CCNCC2)OC(C)C)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)C(C)C)Cl VERWOWGGCGHDQE-UHFFFAOYSA-N 2014 US-7153964-B2 Achiral Molecule CERITINIB
LDK-378
LDK378
NVP-LDK-378-NX
NVP-LDK378-NX
ZYKADIA
Y
Dacomitinib
Vizimpro 4 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'1C9' 4i23 4i24 1 1.0 469.2 5.2 79.4 6.0 2.0 7.0 On october 27, 2018, the FDA approved dacomitinib to treat metastatic non-small-cell lung cancer EGFR Tyr COc1cc2c(cc1NC(=O)/C=C/CN3CCCCC3)c(ncn2)Nc4ccc(c(c4)Cl)F LVXJQMNHJWSHET-AATRIKPKSA-N 2018 US-7772243-B2 Achiral Molecule DACOMITINIB
DACOMITINIB HYDRATE
PF-00299804
Y 184-187 ºC
Crizotinib
Xalkori 4 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'VGH' 2wgj 2xp2 2yfx 3zbf 4anq 4ans 4c9w 5aaa 5aab 5aac 6imz 1 1.0 449.1 5.0 78.0 6.0 2.0 5.0

Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.

ALK
MET
Tyr C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC4 KTEIFNKAUNYNJU-GFCCVEGCSA-N 2011 US-7230098-B2 Single Stereoisomer CRIZOTINIB
PF-02341066
PF-2341066
XALKORI
Y
Afatinib
Gilotrif;Giotrif 4 Boehringer Ingelheim ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'0WM' 4g5j 1 0.0 485.2 4.4 88.6 7.0 2.0 8.0

Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

EGFR
ERBB2
ERBB4
Tyr CN(C)C/C=C/C(=O)Nc1cc2c(cc1O[C@H]3CCOC3)ncnc2Nc4ccc(c(c4)Cl)F ULXXDDBFHOBEHA-CWDCEQMOSA-N 2013 US-RE43431-E1 Single Stereoisomer AFATINIB
BIBW-2992
BIBW2992
GILOTRIF
GIOTRIF
Y
Alectinib
Alecensa 4 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'EMH' 3aox 5xv7 1 0.0 482.3 4.8 72.4 5.0 1.0 3.0

Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

ALK Tyr CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C KDGFLJKFZUIJMX-UHFFFAOYSA-N 2015 US-9126931-B2 Achiral Molecule AF-802
AF802
ALECENSA
ALECTINIB
CH-5424802
CH5424802
RO-5424802
RO5424802
Y
Alpelisib
Piqray 4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'1LT' 4jps nan 0.0 441.1 3.8 101.2 5.0 2.0 4.0 On may 2019, FDA approved alpelisib to treat breast cancer PIK3CA Atypical Cc1c(sc(n1)NC(=O)N2CCC[C@H]2C(=O)N)c3ccnc(c3)C(C)(C)C(F)(F)F STUWGJZDJHPWGZ-LBPRGKRZSA-N 2019 US-8227462-B2 Single Stereoisomer ALPELISIB
BYL-719
BYL719
NVP-BYL719
PIQRAY
Y
Anlotinib
4 Advenchen Laboratories ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
nan 0.0 407.2 4.8 82.4 5.0 2.0 6.0

Anlotinib (AL3818) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (VEGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID: 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123.

KDR
FLT4
Tyr Cc1cc2c([nH]1)ccc(c2F)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC KSMZEXLVHXZPEF-UHFFFAOYSA-N nan NaN NaN CATEQUENTINIB N
Apatinib
4 Bukwang Pharmaceutical ChemSpider
PubChem
Guide to Pharmacology
ZINC
nan 1.0 397.2 5.1 90.7 5.0 2.0 5.0

Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. The free-base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.

KDR Tyr N#CC1(CCCC1)c1ccc(cc1)NC(=O)c1cccnc1Nc1cnccc1C MGZNERAVOCFMCU-UHFFFAOYSA-N 2014 NaN NaN
PACLITAXOL
APATINIBMESYLATE
APATINIB GROUP
PEMETREXED
ARM A
S-1
CARBOPLATIN
ARGET THERAPY
SHR-1210
CAPECITABINE
CRYOABLATION
NAVELBINE+AITAN
IE CHEMOTHERAPY
ESYLATE APATINIB
OXALIPLATIN
AI TAN
YEW
EMOZOLOMIDE(TMZ)
VP-16
SPA
REATMENT GROUP
EGAFUR
APATINIB 750MG
YN968D1
ATAN
APATINIB
APATINIB TABLETS
APATINIB MESYLAS
H20140103
PLATINU
APATINIB MESYLATE
AITAN
APATINIB 500MG
5-FLUOROURACIL
S1
ALBUMIN PACLITAXEL
XELOX
EMOZOLOMIDE
YN968D1,(AITAN®
NO.
STUDY DRUG
DOCETAXEL
RIVOCERANIB
N
Avapritinib
Ayvakit 4 Blueprint Medicines ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
nan 0.0 498.2 2.6 106.3 10.0 1.0 5.0 On January 2020 FDA approved avapritinib to treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) nan C[C@](c1ccc(cc1)F)(c2cnc(nc2)N3CCN(CC3)c4c5cc(cn5ncn4)c6cnn(c6)C)N DWYRIWUZIJHQKQ-SANMLTNESA-N 2020 US-9200002-B2 Single Stereoisomer 70C366
AVAPRITINIB
AYVAKIT
BLU-285
C-366
X-720776
X720776
Y
Axitinib
Inlyta 4 Pfizer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'AXI' 4ag8 4agc 4twp 4wa9 2 0.0 386.1 4.6 70.7 4.0 2.0 5.0 Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer. FLT1
KDR
FLT4
Tyr CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4 RITAVMQDGBJQJZ-FMIVXFBMSA-N 2012 US-6534524-B1 Achiral Molecule AG-013736
AG-13736
AXITINIB
INLYTA
Y
Baricitinib
Olumiant 4 Eli Lilly ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'3JW' 4w9x 6vn8 6wto 1 0.0 371.1 1.1 120.6 7.0 1.0 5.0

Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.

JAK1
JAK2
Tyr CCS(=O)(=O)N1CC(C1)(CC#N)n2cc(cn2)c3c4cc[nH]c4ncn3 XUZMWHLSFXCVMG-UHFFFAOYSA-N 2017 US-8158616-B2 Achiral Molecule BARICITINIB
INCB-028050
INCB-28050
INCB028050
LY-3009104
LY3009104
OLUMIANT
Y
Binimetinib
Mektovi 4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
'QO7' 7m0u nan 0.0 440.0 3.0 88.4 6.0 3.0 6.0

On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

MAP2K1 STE Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3F)Br)C(=O)NOCCO ACWZRVQXLIRSDF-UHFFFAOYSA-N 2018 US-7777050-B2 Achiral Molecule ARRY 438162
ARRY-162
ARRY-438162
BINIMETINIB
MEK-162
MEK162
MEKTOVI
NVP-MEK162
Y
Bosutinib
Bosulif 4 Wyeth ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'DB8' 3soa 3ue4 4mxo 4mxx 4mxy 4mxz 4qmn 5ajq 5i9x 5vc3 5vcy 6fdy 6op9 1 2.0 529.2 5.2 82.9 8.0 1.0 9.0

Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.

BCR
ABL1
LYN
HCK
SRC
CDK2
MAP2K1
MAP2K2
MAP3K2
CAMK2G
CMGC
CAMK
STE
Tyr
Atypical
CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(cc4Cl)Cl)OC UBPYILGKFZZVDX-UHFFFAOYSA-N 2012 US-7417148-B2 Achiral Molecule BOSULIF
BOSUTINIB
BOSUTINIB MONOHYDRATE
SK-606
SKI-606
Y
Brigatinib
Alunbrig 4 Ariad Pharmaceuticals ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
ZINC
FDA SRS
BindingDB
'6GY' 6mx8 7aem 1 2.0 583.3 5.1 85.9 9.0 2.0 8.0

The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules. The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival. Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.

ALK
EGFR
Tyr CN1CCN(CC1)C2CCN(CC2)c3ccc(c(c3)OC)Nc4ncc(c(n4)Nc5ccccc5P(=O)(C)C)Cl AILRADAXUVEEIR-UHFFFAOYSA-N 2017 US-9012462-B2 Achiral Molecule ALUNBRIG
AP-26113
AP26113
BRIGATINIB
Y
Capmatinib
4 Novartis ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
nan 0.0 412.1 3.4 85.1 6.0 1.0 4.0 On may 2020 FDA approved capmatinib to treat patients with non small cell lung cancer MET Tyr CNC(=O)c1ccc(cc1F)c2cnc3ncc(n3n2)Cc4ccc5c(c4)cccn5 LIOLIMKSCNQPLV-UHFFFAOYSA-N 2020 US-7767675-B2 Achiral Molecule CAPMATINIB
INC-280
INC280
INCB-28060
INCB-28060 FREE BASE
NVP-INC280
NVP-INC280-NX
NYP-INC280-NX
Y
Cobimetinib
Cotellic 4 Hoffmann-La Roche ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'EUI' 4an2 4lmn 7juy 7m0v 3 1.0 531.1 3.8 64.6 4.0 3.0 4.0

For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.

MAP2K1 STE c1c(cc(c(c1)Nc2c(c(ccc2C(=O)N3C[C@@](C3)(O)[C@H]4NCCCC4)F)F)F)I BSMCAPRUBJMWDF-KRWDZBQOSA-N 2015 US-7803839-B2 Single Stereoisomer COBIMETINIB
COTELLIC
GDC-0623
GDC-0973
RG 7420
RG-7420
RG-7421
RG7420
XL-518
Y
Gefitinib
Iressa 4 Astrazeneca ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'IRE' 2ito 2ity 2itz 3ug2 4i22 4wkq 5y7z 5y80 1.5 0.0 446.2 4.3 68.7 7.0 1.0 8.0

For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

EGFR Tyr COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F XGALLCVXEZPNRQ-UHFFFAOYSA-N 2003 None Achiral Molecule GEFITINIB
IRESSA
ZD-1839
ZD1839
Y
Copanlisib
Aliqopa 4 Bayer ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'6E2' 5g2n 1 1.0 480.2 0.7 139.8 11.0 2.0 7.0 Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. PIK3CA
PIK3CB
Atypical COc1c(ccc2c1N=C(N3C2=NCC3)NC(=O)c4cnc(nc4)N)OCCCN5CCOCC5 PZBCKZWLPGJMAO-UHFFFAOYSA-N 2017 US-7511041-B2 Achiral Molecule BAY 80-6946
BAY-80-6946
BAY80-6946
COPANLISIB
Y
Dabrafenib
Tafinlar 4 GlaxoSmithKline ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'P06' 4xv2 5csw 5hie 6hj2 6v2u 1.5 2.0 519.1 5.4 110.9 7.0 2.0 5.0

Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

BRAF
RAF1
SIK1
NEK11
LIMK1
CAMK
TKL
NEK
CC(C)(C)c1nc(c(s1)c2ccnc(n2)N)c3cccc(c3F)NS(=O)(=O)c4c(cccc4F)F BFSMGDJOXZAERB-UHFFFAOYSA-N 2013 US-7994185-B2 Achiral Molecule DABRAFENIB
GSK-2118436
GSK-2118436A
GSK2118436
GSK2118436A
TAFINLAR
Y
Tepotinib
4 Merck ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB
'3E8' 4r1v 1 0.0 492.2 4.0 96.9 8.0 0.0 7.0 On February 2021, FDA approved tepotinib to treat non-small cell lung cancer MET Tyr CN1CCC(CC1)COc2cnc(nc2)c3cccc(c3)Cn4c(=O)ccc(n4)c5cccc(c5)C#N AHYMHWXQRWRBKT-UHFFFAOYSA-N 2021 None Achiral Molecule EMD 1214063
EMD-1214063
EMD1214063
MSC-2156119
MSC-2156119J
MSC2156119
TEPOTINIB
Y

(*) indicates that the target is not a kinase